

1992 INDEX

A

Abdomen

- abscess, and pleural effusion, May, 315-316
- CT scans in unknown primary malignancy, Apr., 228
- examination in cardiac evaluation, June, 379
- surgery, pleural effusion after, May, 316

Abscess

- intra-abdominal, and pleural effusion, May, 315-316
- lung, differentiated from empyema, May, 301
- periurethral, after chronic indwelling catheter, in elderly, Feb., 136

Absorbent pads and garments: for geriatric urinary incontinence, Feb., 120

Acetylcholine in Alzheimer's disease, Jan., 45-46

- cognitive therapy for deficits in (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)

Acid

- base disturbances, July, 562-564
- metabolic, July, 563-564
- respiratory, July, 562-563
- hydrolases in platelet lysosomes, Aug., 598

Acidemia

- metabolic, July, 564
- respiratory, July, 562

Acidosis

- metabolic, July, 564
- respiratory, July, 562

Acquired immunodeficiency syndrome (see AIDS)

Acyclovir in AIDS

- for herpes simplex infection, Oct., 734
- for leukoplakia, oral hairy, Oct., 735

for varicella-zoster virus infection, Oct., 734-735

zidovudine combined with, Oct., 716

Addison's disease: and dementia, Jan., 31

Adenocarcinoma of unknown primary origin, Apr., 252, 254

chemotherapy, Apr., 248

Adenoma: adrenal, and polycythemia, Mar., 186

Adenosine

deaminase in exudative pleural effusions, May, 284

diphosphate-induced platelet aggregation, Aug., 593

Adenovirus infection: in AIDS, Oct., 736

Adolescent: polycythemia vera in, Mar., 170

ADP-induced platelet aggregation, Aug., 593

Adrenal adenoma: and polycythemia, Mar., 186

Advance directives: for Alzheimer's patients, Jan., 36-37

Advocacy: for Alzheimer's patients, Jan., 36-37

Aerobic glycolysis: in multiple organ failure syndrome, Dec., 867-869

Afibrinogenemia: congenital, and platelet aggregation disorder, Aug., 605

Afipia felis infections: in AIDS, Oct., 745

AFP (see α -Fetoprotein)

Age

-associated memory impairment, Jan., 17

myeloid metaplasia and, agnogenic, Mar., 170

thrombocythemia and, essential, Mar., 170

-related changes in urination, Feb., 87-92

Aggregometer, Aug., 592

1992 INDEX

A

Abdomen

- abscess, and pleural effusion, May, 315-316
- CT scans in unknown primary malignancy, Apr., 228
- examination in cardiac evaluation, June, 379
- surgery, pleural effusion after, May, 316

Abscess

- intra-abdominal, and pleural effusion, May, 315-316
- lung, differentiated from empyema, May, 301
- periurethral, after chronic indwelling catheter, in elderly, Feb., 136

Absorbent pads and garments: for geriatric urinary incontinence, Feb., 120

Acetylcholine in Alzheimer's disease, Jan., 45-46

- cognitive therapy for deficits in (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)

Acid

- base disturbances, July, 562-564
- metabolic, July, 563-564
- respiratory, July, 562-563
- hydrolases in platelet lysosomes, Aug., 598

Acidemia

- metabolic, July, 564
- respiratory, July, 562

Acidosis

- metabolic, July, 564
- respiratory, July, 562

Acquired immunodeficiency syndrome (see AIDS)

Acyclovir in AIDS

- for herpes simplex infection, Oct., 734
- for leukoplakia, oral hairy, Oct., 735

for varicella-zoster virus infection, Oct., 734-735

zidovudine combined with, Oct., 716

Addison's disease: and dementia, Jan., 31

Adenocarcinoma of unknown primary origin, Apr., 252, 254

chemotherapy, Apr., 248

Adenoma: adrenal, and polycythemia, Mar., 186

Adenosine

deaminase in exudative pleural effusions, May, 284

diphosphate-induced platelet aggregation, Aug., 593

Adenovirus infection: in AIDS, Oct., 736

Adolescent: polycythemia vera in, Mar., 170

ADP-induced platelet aggregation, Aug., 593

Adrenal adenoma: and polycythemia, Mar., 186

Advance directives: for Alzheimer's patients, Jan., 36-37

Advocacy: for Alzheimer's patients, Jan., 36-37

Aerobic glycolysis: in multiple organ failure syndrome, Dec., 867-869

Afibrinogenemia: congenital, and platelet aggregation disorder, Aug., 605

Afipia felis infections: in AIDS, Oct., 745

AFP (see α -Fetoprotein)

Age

-associated memory impairment, Jan., 17

myeloid metaplasia and, agnogenic, Mar., 170

thrombocythemia and, essential, Mar., 170

-related changes in urination, Feb., 87-92

Aggregometer, Aug., 592

- Aggressiveness: in Alzheimer's disease, management, Jan., 38-39
 Agnogenic myeloid metaplasia: and age, Mar., 170
 AIDS, Sept., 646-690; Oct., 705-764
 (See also HIV)
 bacterial infections in, Oct., 744-745
 candidiasis in, Oct., 740-741
 chemotherapy in, antiviral, Oct., 705-716
 guidelines, Oct., 717-719
 cryptococcosis in, Oct., 741-743
 cryptosporidiosis in, Oct., 728-729
 cytomegalovirus infection in, Oct., 730-733
 diagnosis, Sept., 669-672
 didanosine in (see Didanosine in AIDS)
 dideoxycytidine in (see Dideoxycytidine in AIDS)
 epidemiology, worldwide, Sept., 667-669
 Epstein-Barr virus infection in, Oct., 735
 fungal infections in, Oct., 740-744
 herpes simplex virus infection in, Oct., 733-734
 immunomodulators in, Oct., 720
 infections, malignancies, and neurologic syndromes associated with, Sept., 657
 infectious complications, Oct., 720-745
 isosporiasis in, Oct., 729-730
 Kaposi's sarcoma in, Oct., 746-748
 pleural effusions and, May, 311
 lymphoma in, non-Hodgkin's, Oct., 748-749
 mycobacterial infections in Oct., 736-740
 Mycobacterium avium complex disease in, Oct., 736-738
 Mycobacterium tuberculosis infection in, Oct., 738-739
 natural history, Sept., 653, 655-658
 neoplastic complications, Oct., 720-721, 746-750
 opportunistic infections in, treatment regimens, Oct., 724-725
 pathogenesis, Sept. 652-655
 pleural effusions in, May, 311
 Pneumocystis carinii disease in, Oct., 721-726
 protozoan infections in, Oct., 721-730
 reverse transcriptase inhibitors in, Oct., 715-716
 therapy, Oct., 705-720
 combination, Oct., 716
 toxoplasmosis in, Oct., 726-728
 vaccines in, Oct., 720
 varicella-zoster virus infection in, Oct., 734-735
 viral infections in, Oct., 730-736
 zidovudine in (see Zidovudine in AIDS)
- Air distribution: effect of localized airway obstruction on, July, 546
- Airflow limitation
 compliance in, effect of respiratory frequency increase on, July, 548
 static volume-pressure curve in, July, 525
 resistance (see Flow resistance)
 volume relationship during forced vital capacity maneuver, July, 537
- Airway conductance, relationship to lung volume, July, 536
- obstruction, localized
 effect on air distribution, July, 546
 effect on volume-pressure relationship, July, 547
- peripheral, flow resistance in, July, 543
- resistance
 (See also Flow resistance)
 effect of inhaled methacholine or histamine on, July, 550

- Airway (cont.)
relationship between lung volume and, July, 536
responsiveness tests, July, 548–551
- Albinism: platelet granule deficiency in, Aug., 608
- Albumin excretion: urinary, effect of enalapril or metoprolol in diabetic nephropathy on, Nov., 824
- Alcohol: and hypertension, Nov., 803
- Alkalemia
metabolic, July, 564
respiratory, July, 563
- Alkaline phosphatase: leukocyte, in polycythemia vera, Mar., 177, 178
- Alkalosis
metabolic, July, 564
respiratory, July, 563
- Alkytating agents: in polycythemia vera, Mar., 195
- Allopurinol: for gout in polycythemia vera, Mar., 197
- Alpha-adrenergic blocker in geriatric urinary incontinence overflow, Feb., 131
stress, Feb., 130
- Alpha-fetoprotein (see α -Fetoprotein)
- Altitude: high, and polycythemia, Mar., 185
- Aluminum exposure: and Alzheimer's disease, Jan., 15
- Alveolar
hypoventilation and polycythemia, Mar., 185
ventilation, July, 553–555
- Alzheimer's disease, Jan., 13–64
acetylcholine in, Jan., 45–46
therapy targeted toward (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)
advance directives and, Jan., 36–37
advocacy and, Jan., 36–37
- aggressiveness in, management, Jan., 38–39
- anatomy
neurochemical, Jan., 45–47
pathologic, macroscopic, Jan., 40
pathologic, microscopic, Jan., 40–45
- ancillary tests in, Jan., 23–26
- clinical evaluation for, Jan., 16–26
- community resources, Jan., 35–36
- course, Jan., 18–21
- criteria for, NINCDS-ADRDA, Jan., 18
- day care for, Jan., 35
- defining, Jan., 18
- depression in, management, Jan., 38
- driving and, Jan., 37
- drugs in, Jan., 49
- epidemiology, Jan., 13–16
- genetics of, Jan., 26–27
- guardianship and, Jan., 37
- hospice care in, Jan., 36
- management
behavioral, Jan., 37–39
medical, Jan., 34–39
- neuritic plaques in, Jan., 41–43
- neurofibrillary tangles in, Jan., 43–44
- neurologic examination in, Jan., 22–23
- neuropsychological performance testing in, Jan., 22
- neurotransmitters in, aminergic, Jan., 46
- cognitive therapy directed toward, Jan., 29
- nootropics in, Jan., 49
- nursing home special care units for, Jan., 36
- pathology, Jan., 39–45
- power of attorney and, Jan., 37
- presentation, Jan., 18–21
- prevalence, Jan., 14
estimated, in U.S. by year 2050, Jan., 15
- public health impact, Jan., 13–16
- radiology in (see Radiology, in Alzheimer's disease)

- respite care in, Jan., 35–36
 sleep/wake disturbances in, management, Jan., 38
 somatostatin in, Jan., 46–47
 therapy
 cognitive, experimental (see
 Cognitive, therapy, experimental, in Alzheimer's disease)
 noncognitive, Jan., 35–37
 Amebiasis: pleural, May, 309
 Amiloride: in hypertension, in elderly, Nov., 822
 Aminergic neurotransmitters in Alzheimer's disease, Jan., 46
 cognitive therapy directed toward, Jan., 49
 Amiodarone: causing pleural effusion, May, 319
 Amphotericin B
 in aspergillosis
 in AIDS, Oct., 744
 pleural, May, 307
 in blastomycosis, pleural, May, 307
 in coccidioidomycosis
 in AIDS, Oct., 744
 pleural, May, 308
 in cryptococcosis
 in AIDS, Oct., 742–743
 pleural, May, 308
 in histoplasmosis in AIDS, Oct., 743
 Amylase: pleural fluid, in exudative pleural effusions, May, 282–283
 Amyloid
 cerebrovascular, in Alzheimer's disease, Jan., 43
 precursor protein in Alzheimer's disease, Jan., 43
 Amyloidosis: cardiac, endomyocardial biopsy in, June, 488
 Anabolic steroids: for anemia in postpolycythemic myeloid metaplasia, Mar., 202
 Anagrelide: in polycythemia vera, Mar., 191
 Androgens: and polycythemia, Mar., 186
- Anemia
 in myeloid metaplasia, postpolycythemic
 chemotherapy for, Mar., 202
 erythropoietin in, recombinant, Mar., 202
 splenectomy for, Mar., 203
 splenectomy for, acute leukemia after, Mar., 201
 steroids in, anabolic, Mar., 202
 therapy, Mar., 201–203
 zidovudine-induced, Oct., 709–710
- Angina
 as end point of exercise testing, June, 413
 new-onset, thallium imaging in, June, 462
- Angiocardiogram: equilibrium radionuclide, June, 456–457
- Angloendotheliomatosis: and dementia, Jan., 32
- Angiogenesis, Apr., 225
- Angiography: coronary, interpretation, June, 469–470
- Angiotensin-converting enzyme inhibitors: in hypertension in diabetics, Nov., 823–824
- Anomaly
 Ebstein's, echocardiography in, June, 439
 May-Hegglin, Aug., 602
- Antibiotics: beta lactam, causing platelet dysfunction, Aug., 612
- Antibody
 anticellular, pleural fluid, measurement in lupus pleuritis, May, 318
 antiplatelet, and acquired platelet disorders, Aug., 616–617
 monoclonal, in multiple organ failure syndrome therapy, Dec., 884–885
- Anticoagulants: causing platelet dysfunction, Aug., 612–613
- Antidepressants
 in Alzheimer's disease, Jan., 38
 platelet dysfunction due to, Aug., 613

- Antifibrinolytic agents:** for platelet function disorders, Aug., 622
- Antigen**
- carcinoembryonic, in unknown primary malignancy, Apr., 231
 - challenge, effect on airway resistance in antigen-induced asthma, July, 550
 - HIV, in HIV diagnosis, Sept., 675–676
 - prostate-specific immunocytochemical stain for, Apr., 237
 - in malignancy of unknown primary origin, Apr., 232
 - specific response system in multiple organ failure syndrome, Dec., 877
- Antihistamines:** causing platelet dysfunction, Aug., 613
- Antihypertensive drugs** (*see Drug therapy in hypertension*)
- Antiinflammatory agents, nonsteroidal**
- hemorrhage in polycythemia vera due to, Mar., 172
 - platelet dysfunction due to, Aug., 611
- Antinuclear antibody:** pleural fluid, measurement in lupus pleuritis, May, 318
- Antiplatelet antibodies:** and acquired platelet disorders, Aug., 616–617
- Antipsychotics:** causing platelet dysfunction, Aug., 613
- Antithrombotics:** causing platelet dysfunction, Aug., 612–613
- Antiviral chemotherapy in AIDS,** Oct., 705–716
- guidelines, Oct., 717–719
- Aortic**
- coarctation on chest radiography, June, 407–409
 - disease, MRI in, June, 465
 - dissections, transesophageal echocardiography in, June, 427
- regurgitation, June, 481–483**
- cardiac catheterization in, June, 481–482
 - cardiac catheterization in, for prognosis assessment, June, 482–483
 - echocardiography in, June, 437, 438
 - hemodynamic assessment, June, 482
- stenosis** (*see Stenosis, aortic*)
- valve, bicuspid, echocardiography of, June, 454**
- Aphasia:** progressive, and dementia, Jan., 33
- Apical impulse:** left ventricular, June, 368
- Apnea:** sleep, and drug therapy in hypertension, Nov., 824–825
- Apoplexy:** pulmonary, June, 361
- Apoptosis, Dec., 877**
- Aprotinin:** in cardiac bypass surgery, Aug., 616
- Arginine:** in multiple organ failure syndrome, Dec., 885
- Arrhythmias**
- in cor pulmonale, June, 392
 - exercise-induced, June, 415
- Artery(ies)**
- coronary (*see Bypass, coronary artery*)
 - hypoxemia, causing polycythemia, Mar., 185
- pressures in cardiac evaluation, June, 365–368**
- pulse** (*see Pulse, arterial*)
- Arthritis:** rheumatoid, pleural effusion in, May, 317
- Arthropods:** HIV transmission by, Sept., 665
- Artificial insemination:** HIV transmission by, Sept., 664
- Asbestos exposure:** causing pleural effusion, May, 320
- Ascites, cirrhosis, and pleural effusion** (*see Hydrothorax, hepatic*)
- A68:** in Alzheimer's disease, Jan., 44
- Aspergillosis**
- in AIDS, Oct., 744
 - pleural, May, 307

- A**
- Aspirin
 /dipyridamole in polycythemia vera, Mar., 191
 effect on platelet aggregation, Aug., 594
 platelet dysfunction due to, Aug., 609–611
- Asthma
 airway resistance in, effect of inhaled methacholine or histamine on, July, 550
 antigen-induced, effect of antigen challenge on airway resistance in, July, 550
 dyspnea in, June, 357–358
 flow resistance in, July, 534
 pulsus paradoxus in, June, 368
- Atherosclerotic complications: in polycythemia vera, Mar., 171
- Atrial enlargement
 ECG in (see Electrocardiogram, in atrial enlargement)
 echocardiography, June, 450
 on radiography, chest, June, 401–403
 septal defect (see Septal defect, atrial)
 tachycardia, multifocal, in cor pulmonale, June, 392
 thrombi, echocardiography in, June, 452–453
 transesophageal, June, 427–428
- Auscultation, cardiac, June, 369–372
 dynamic, June, 377–378
 during handgrip, June, 378
 after premature ventricular contraction beats, June, 378
 during squatting, June, 377
 during Valsalva, June, 377
- 3'-Azido-2',3'-dideoxythymidine (see Zidovudine)
- Azithromycin in AIDS
 for cryptosporidiosis, Oct., 729
 for *Mycobacterium avium* complex disease, Oct., 728
 for toxoplasmosis, Oct., 728
- Azotemia: prerenal, after resuscitation, Dec., 872
- AZT (see Zidovudine)
- B**
- Bacterial infections
 in AIDS, Oct., 744–745
 of pleural space (see Parapneumonic effusions and bacterial infections of pleural space)
- Bacteriologic stains: in exudative pleural effusions, May, 283
- Bacteriology: of parapneumonic effusions, May, 299–300
- Bacteriuria, in elderly, Feb., 90–91
 pyuria and, in men, Feb., 106
 treatment, Feb., 91–92
- Barium enema: in unknown primary malignancy, Apr., 229
- B cells: in HIV infection, Sept., 672
- Beats: premature ventricular contraction, auscultation after, June, 378
- Behavioral disturbances in Alzheimer's disease, Jan., 20
 management of Alzheimer's disease, Jan., 37–39
 therapies in geriatric urinary incontinence, Feb., 120–127
 caregiver-dependent, Feb., 124–127
 caregiver-dependent, examples, Feb., 124
 patient-dependent, Feb., 121–124
 patient-dependent, examples, Feb., 122
 training in geriatric urinary incontinence, Feb., 121–123
- Bernard-Soulier syndrome, Aug., 600–602
- Beta-blockers in hypertension in elderly, Nov., 812–813, 822
 as initial therapy, Nov., 814, 815
- Beta lactam antibiotics: causing platelet dysfunction, Aug., 612
- Bethanechol
 in Alzheimer's disease, Jan., 48
 in incontinence, geriatric overflow urinary, Feb., 131
- BHAP compounds: in AIDS, Oct., 716

- Bicuspid aortic valve: echocardiography, June, 454
- Biofeedback: for geriatric urinary incontinence, Feb., 121
- Biologic principles: in unknown primary malignancy, Apr., 245–246
- Biopsy**
- bone marrow, in postpolycythemic myeloid metaplasia, Mar., 200
 - endomyocardial, June, 487–490
 - gastric, and aspirin and platelet dysfunction, Aug., 611
 - pleural
 - needle, in mesothelioma, malignant, May, 297
 - needle, in pleural effusions, exudative, May, 285–286
 - needle, in pleural effusions, malignant, May, 293
 - open, in exudative pleural effusions, May, 287
- Bioptome: Stanford, in endomyocardial biopsy, June, 488–489
- BIRG-587: in AIDS, Oct., 715–716
- Bisferiens pulse, June, 367
- Bisheteroarylpiperazine compounds: in AIDS, Oct., 715–716
- Bladder**
- carcinoma, laboratory studies in, Feb., 106
 - contractility impairment with detrusor hyperactivity causing incontinence, in elderly, Feb., 98–99
 - function changes, age-related, Feb., 87–88
 - records in evaluation of geriatric urinary incontinence, Feb., 102–103
 - in ambulatory clinic settings, Feb., 104
 - in institutional settings, Feb., 105
 - relaxants in geriatric incontinence, Feb., 130
 - retraining in geriatric incontinence, Feb., 121–124
- Blastomycosis: pleural, May, 307
- Bleomycin: in malignant pleural effusions, May, 294, 295
- Blessed Orientation, Memory Concentration Test: in Alzheimer's disease, Jan., 22
- Blood**
- carbon dioxide transport in, July, 561
 - cells
 - red (*see Red cell*)
 - white (*see Leukocyte*)
 - chemistries, effects of diuretic dosage on, Nov., 815
 - flow
 - cerebral, in polycythemia vera, Mar., 171
 - in lung, upright, July, 556
 - gas transport in, July, 559–564
 - oxygen transport in, July, 560–561
 - pressure
 - effects of diuretic dosage on, Nov., 815
 - effects of enalapril or metoprolol in diabetic nephropathy on, Nov., 824
 - measurement in cardiac evaluation, June, 365–366
 - measurement technique recommended by British Hypertension Society, Nov., 785
 - monitoring, Nov., 784–788
 - monitoring, ambulatory, Nov., 787–788
 - monitoring, out-of-the-office, Nov., 784–786
 - monitoring, out-of-the-office, during therapy, Nov., 786–787
 - monitoring, during therapy, Nov., 786–787
 - relation to risk of cardiovascular disease, Nov., 827
 - response during exercise testing, abnormal, June, 414
 - products, HIV transmission by, Sept., 663–664
- Body**
- composition alteration in multiple organ failure syndrome, Dec., 866–867

- mass, lean, after resuscitation, Dec., 867
- plethysmograph, measurement of airway resistance in, July, 535
- Bone**
- marrow
 - biopsy in postpolycythemic myeloid metaplasia, Mar., 200
 - cytogenetics in polycythemia vera, Mar., 182
 - location in polycythemia vera, Mar., 179-181
 - morphology in polycythemia vera, Mar., 181
 - in polycythemia vera, MRI of, Mar., 180
 - transplant in Glanzmann's thrombasthenia, in children, Aug., 605
 - scans in unknown primary malignancy, Apr., 230
- Breast**
- cancer (see Cancer, breast)
 - feeding and HIV transmission, Sept., 663
 - Breath sounds, June, 378-379
 - Breathing: control of, July, 564-565
 - Bromocriptine: causing pleural effusion, May, 319
 - Bronchial vein varices: causing hemoptysis in mitral stenosis, June, 361
 - Bronchitis: winter, causing hemoptysis in mitral stenosis, June, 362
 - Bronchoalveolar lavage: in diagnosis of *Pneumocystis carinii* pneumonia in AIDS, Oct., 722
 - Bronchodilators: effect on ventilatory pattern in obstructive disease, July, 540, 541, 542
 - Bronchoscopy: in exudative pleural effusions, May, 286
 - Bruce exercise test protocol: standard, June, 415-416
 - Budd-Chiari syndrome: and polycythemia vera, Mar., 171
 - Busulfan
 - in myeloproliferative disorders, Aug., 618

in polycythemia vera, Mar., 196

Bypass

 - cardiac
 - DDAVP in, Aug., 621
 - platelet dysfunction due to, Aug., 615-616

coronary artery

 - aspirin and platelet dysfunction, Aug., 611

pleural effusion after, May, 321

C

- CA**
- 15-3 in unknown primary malignancy, Apr., 233-235
 - 19-9 in unknown primary malignancy, Apr., 234
 - 125 in unknown primary malignancy, Apr., 233
- Caffeine: and coffee, Nov., 808-809
- Calcium**
- channel blockers
 - in hypertension, in diabetics, Nov., 823-824
 - in hypertension; in elderly, Nov., 822
 - in incontinence, urge, in elderly, Feb., 127-130
 - platelet dysfunction due to, Aug., 613
 - supplements in hypertension, Nov., 806
- Campylobacter infections:** in AIDS, Oct., 744
- Cancer**
- breast
 - CA 125 in, Apr., 233-234
 - cytogenetic analysis, Apr., 241
 - epidermal growth factor in, Apr., 246
 - colon, cytogenetic analysis, Apr., 241
 - colorectal, CA 19-9 in, Apr., 234
 - gastric, CA 19-9 in, Apr., 234
 - hepatobiliary, CA 19-9 in, Apr., 234
 - invasive, transition to, Apr., 225
 - ovarian, CA 125 in, Apr., 233
 - pancreas, CA 19-9 in, Apr., 234

- Cancer (cont.)**
- prostate
 - disseminated, Apr., 252
 - immunocytochemical stain for prostate-specific antigen in, Apr., 237
 - Candidiasis: in AIDS, Oct., 740-741
 - Captopril challenge test: for renovascular hypertension, Nov., 821
 - Carbamazepine: in Alzheimer's disease, Jan., 39
 - Carbenicillin-induced platelet dysfunction, Aug., 612
 - Carbon dioxide
 - respiratory response to, July, 564-565
 - tension, pleural fluid, in exudative pleural effusions, May, 284
 - transport in blood, July, 561
 - Carboxyhemoglobin: and polycythemia, Mar., 185-186
 - Carcinoembryonic antigen: in unknown primary malignancy, Apr., 231
 - Carcinoma
 - adenocarcinoma of unknown primary origin, Apr., 252, 254
 - chemotherapy, Apr., 248
 - bladder, laboratory studies in, Feb., 106
 - neuroendocrine, poorly differentiated, Apr., 251-252
 - squamous cell, of unknown primary origin, Apr., 249
 - Cardiac (see Heart)
 - Cardiology, nuclear, June, 455-463
 - first-pass studies, June, 457-458
 - exercise, June, 458
 - of right ventricular function, June, 458-459
 - imaging principles, June, 456
 - techniques for assessing cardiac function, June, 456-459
 - Cardiomyopathy
 - dilated
 - echocardiography of left ventricular systolic function in, June, 443-444
 - endomyocardial biopsy in, June, 487-488
 - hypertrophic, endomyocardial biopsy in, June, 487-488
 - restrictive, cardiac catheterization in, June, 483-486
 - Cardiorespiratory adaptation to exercise, July, 566-571
 - poor cooperation and, July, 571
 - Cardiotoxicity: doxorubicin, endomyocardial biopsy in, June, 488
 - Cardiovascular
 - disease risk related to blood pressure, Nov., 827
 - limitation during exercise, July, 569-570
 - Care
 - day, for Alzheimer's patients, Jan., 35
 - hospice, in Alzheimer's disease, Jan., 36
 - respite, in Alzheimer's disease, Jan., 35-36
 - supportive, for platelet function disorders, Aug., 619
 - Catabolic rate: after resuscitation, Dec., 871
 - Catabolism: total body protein, after resuscitation, Dec., 871-872
 - Catheter in geriatric urinary incontinence, Feb., 134-138
 - external, Feb., 134
 - in dwelling, chronic, Feb., 135-138
 - Catheterization
 - cardiac, June, 465-490
 - in aortic regurgitation, June, 481-482
 - in aortic regurgitation, for prognosis assessment, June, 482-483
 - in aortic stenosis, June, 473-476
 - in cardiomyopathy, restrictive, June, 483-486
 - indications, June, 465-466
 - in mitral regurgitation, June, 477-479

- in mitral regurgitation, for prognosis assessment, June, 479-481
- in mitral stenosis, June, 470-473
- in myocardial disease, June, 483-487
- in pericardial disease, June, 483-487
- in pericarditis, constrictive, June, 483-486
- in tamponade, cardiac, June, 486-487, 488, 489
- techniques, June, 466-467
- in tricuspid regurgitation, June, 481
- in tricuspid stenosis, June, 473
- in valvular heart disease, June, 470-483
- intermittent, in geriatric urinary incontinence, Feb., 135
- Cat scratch disease: in AIDS, Sept., 671; Oct., 745
- CEA: in unknown primary malignancy, Apr., 231
- Cell
- B, in HIV infection, Sept., 672
 - blood (see Blood, cells)
 - endothelial, in multiple organ failure syndrome, Dec., 875-876
- germ cell tumor (see Germ cell tumor)
- hairy cell leukemia, platelet dysfunction in, Aug., 618
- killer, lymphokine-activated, in metastatic melanoma, Apr., 245
- Central nervous system lymphoma: in AIDS, Oct., 748-749
- CERAD neuropsychological testing: in Alzheimer's disease, Jan., 22
- Cerebellar hemangiomas: and polycythemia, Mar., 186
- Cerebral blood flow: in polycythemia vera, Mar., 171
- Cerebrospinal fluid abnormalities: in HIV infection, Sept., 672
- Cerebrovascular amyloid: in Alzheimer's disease, Jan., 43
- Cervical papillomavirus infection: and HIV, Sept., 671
- Chamber, heart (see Heart, chamber)
- Chédiak-Higashi syndrome: dense granule deficiency in, Aug., 608
- Chemotherapy
- of adenocarcinoma of unknown primary origin, Apr., 248
 - agents causing platelet dysfunction, Aug., 613
- antiviral, in AIDS, Oct., 705-716
- guidelines, Oct., 717-719
- of germ cell tumors, gonadal and extragonadal, Apr., 251
- of Kaposi's sarcoma in AIDS, Oct., 747, 748
- of lymphoma, large-cell, Apr., 250-251
- of malignancy of unknown origin, Apr., 248-249
- of mesothelioma, peritoneal, Apr., 253
- of myeloid metaplasia, postpolycythemic, Mar., 202
- Chest
- CT scans in unknown primary malignancy, Apr., 228-229
 - examination in cardiac evaluation, June, 378-379
 - pain in cardiac evaluation, June, 358-359
- radiography (see Radiography, chest)
- tubes
- in parapneumonic effusions (see Parapneumonic effusions and bacterial infections of pleural space, chest tube drainage in)
 - in pleural effusions after Fontan procedure, May, 291
- Children
- AIDS in, zidovudine in, Oct., 707
 - DDAVP in, Aug., 621
 - myelodysplasia with Bernard-Soulier-like platelets in, Aug., 602

- Children (cont.)**
- newborn, polymerase chain reaction for HIV infection in, Sept., 679
 - polycythemia vera in, Mar., 170
 - thrombasthenia in, Glanzmann's, bone marrow transplantation in, Aug., 605
 - Chinese black tree fungus: causing platelet dysfunction, Aug., 613
 - Chlorambucil:** in polycythemia vera, Mar., 195
 - Chlorthalidone:** in hypertension, in elderly, Nov., 822
 - Cholangitis:** sclerosing, with papillary stenosis due to cytomegalovirus in AIDS, Oct., 731
 - Cholecystitis:** cryptosporidial, in AIDS, Oct., 729
 - Cholesterol:** pleural fluid, in exudative pleural effusions, May, 284
 - Cholestyramine:** for pruritus in polycythemia vera, Mar., 196
 - Choline acetyltransferase activity deficits:** in Alzheimer's disease, Jan., 45
 - Cholinergic system (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)**
 - Chorionic gonadotropin:** human, in unknown primary malignancy, Apr., 232
 - Chorioretinitis:** cytomegalovirus, in AIDS, Oct., 731
 - Chromosome abnormalities in Alzheimer's disease:** Jan., 26-27
 - clonal, in marrow cells in polycythemia vera, Mar., 182
 - in solid malignant neoplasms, Apr., 242
 - Churg-Strauss syndrome:** causing pleural disease, May, 318
 - Cigarette smoking (see Smoking)**
 - Cimetidine:** for pruritus in polycythemia vera, Mar., 196
- Cirrhosis**
- ascites and pleural effusion (see Hydrothorax, hepatic)
 - polycythemia and, Mar., 185
- Clamps:** for geriatric urinary incontinence, Feb., 132-133
- Clarithromycin** in AIDS
- for cryptosporidiosis, Oct., 729
 - for *Mycobacterium avium* complex disease, Oct., 738
 - for toxoplasmosis, Oct., 728
- Clindamycin**
- primaquine in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
 - in toxoplasmosis in AIDS, Oct., 727
- Closing capacity**, July, 548
- Closing volume**, July, 548
- Clot retraction**, Aug., 599
- Clubbing:** in cardiac evaluation, June, 380
- CNS lymphoma:** in AIDS, Oct., 748-749
- CO₂ (see Carbon dioxide)**
- Coagulation**
- disseminated intravascular, platelet dysfunction in, Aug., 618
 - in polycythemia vera, Mar., 178-179
- Coarctation of aorta:** on chest radiography, June, 407-409
- Cobalamin deficiency:** and dementia, Jan., 31
- Coccidioidomycosis**
- in AIDS, Oct., 744
 - pleural, May, 307-308
- Coffee:** and hypertension, Nov., 808-809
- Cognitive**
- assessment in Alzheimer's disease, Jan., 17
 - therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits, Jan., 47-49
 - decreased degradation, Jan., 48
 - direct antagonists, Jan., 48
 - future directions, Jan., 48-49
 - increased release, Jan., 47

- precursor loading, Jan., 47
- therapy, experimental, in Alzheimer's disease, for aminergic system deficits, Jan., 49
- Colchicine: in pleural disease due to familial Mediterranean fever, May, 319
- Collagen
- induced platelet aggregation, Aug., 593
 - receptor on platelets, Aug., 591
 - vascular diseases causing pleural disease, May, 317-319
- Colon cancer: cytogenetic analysis, Apr., 241
- Colorectal cancer: CA 19-9 in, Apr., 234
- Color-flow Doppler echocardiography, June, 429-430
- Community resources: for Alzheimer's disease, Jan., 35-36
- Compliance (see Lung, compliance)
- Computed tomography (see Tomography, computed)
- Confusional episode: acute, in elderly medical patients, Jan., 20
- Continence, urinary
- dependency, Feb., 99
 - medications affecting, Feb., 96
 - requirements for, Feb., 92-93
- Contrast agents: radiographic, causing platelet dysfunction, Aug., 613
- Cori cycle: in multiple organ failure syndrome, Dec., 869
- Coronary
- angiography, interpretation, June, 469-470
 - artery bypass (see Bypass, coronary artery)
 - heart disease (see Heart, disease, coronary)
- Cor pulmonale
- arrhythmias in, June, 392
 - atrial tachycardia in, multifocal, June, 392
- ECG in (see Electrocardiogram, in cor pulmonale)
- Corrigan's pulse, June, 367
- Corticosteroids
- in platelet function disorders, Aug., 621
 - in platelet secretion disorders, Aug., 606
 - in pleural disease due to immunoblastic lymphadenopathy, May, 319
 - in pleural effusions, sarcoid, May, 323
 - in *Pneumocystis carinii* disease in AIDS, Oct., 722
- Corynebacterium parvum*: in malignant pleural effusions, May, 295
- Cost
- of bleomycin in malignant pleural effusions, May, 295
 - of drug therapy in hypertension, Nov., 825-826
 - effectiveness of prompted voiding for geriatric urinary incontinence, Feb., 125
 - of laboratory tests in pleural effusions, May, 279-280
 - of urinary incontinence, geriatric, Feb., 83
- Cough: in cardiac evaluation, June, 362
- Crackles: in cardiac evaluation, June, 378-379
- Creutzfeldt-Jakob disease, Jan., 34
- Cryoprecipitate: in uremic patients, Aug., 615
- Cryptococcosis
- in AIDS, Oct., 741-743
 - pleural, May, 308
- Cryptosporidiosis: in AIDS, Oct., 728-729
- CT (see Tomography, computed)
- Culture
- in pleural effusions, exudative, May, 283
 - viral, in-HIV diagnosis, Sept., 677-678
- Cushing's disease: and dementia, Jan., 31
- Cyanosis: ruddy, in polycythemia vera, Mar., 173

- Cyclophosphamide: in polycythemia vera, Mar., 195
- Cyproheptadine: for pruritus in polycythemia vera, Mar., 196
- Cyst: renal, and polycythemia, Mar., 186
- Cystocele
grading system, Feb., 107
incontinence and, geriatric, Feb., 106
- Cystometrogram
filling, Feb., 116
voiding, Feb., 116
- Cystometry: simple, procedure for, Feb., 111
- Cystourethroscopy: in geriatric urinary incontinence, Feb., 113
- Cytogenetics
bone marrow, in polycythemia vera, Mar., 182
of malignancy of unknown origin, Apr., 241-242
- Cytokine effects: of multiple organ failure syndrome, Dec., 866
- Cytology, pleural fluid, in pleural effusions
exudative, May, 282
malignant, May, 293
- Cytomegalovirus infection: in AIDS, Oct., 730-733
- Cytotoxic therapy: in pleural disease due to immunoblastic lymphadenopathy, May, 319
- D**
- Dantrolene: causing pleural effusion, May, 319
- Dapsone in *Pneumocystis carinii* disease in AIDS
prophylactic, Oct., 726
trimethoprim combined with, Oct., 722, 723
- Daunorubicin: causing platelet dysfunction, Aug., 613
- Day care: for Alzheimer's patients, Jan., 35
- DDAVP
in Bernard-Soulier syndrome, Aug., 602
- in gray platelet syndrome, Aug., 607
- in platelet function disorders, Aug., 620-621
- in platelet granule deficiency, dense, Aug., 608
- in platelet secretion disorders, Aug., 606
- in uremic patients, Aug., 615
- ddC (see Dideoxycytidine)
- ddI (see Didanosine)
- Dead space
effect on alveolar ventilation, July, 554
-like ventilation, July, 558
- Death
Alzheimer's disease and, Jan., 21
from coronary heart disease related to cholesterol, blood pressure, and smoking, Nov., 789
- in hypertension related to left ventricular hypertrophy, Nov., 793
- Decortication
in paragonimiasis, pleural, May, 310
- in parapneumonic effusions, May, 303-304
- in pleural histoplasmosis, May, 309
- Delirium: differentiated from dementia, Jan., 28
- Dementia
adult, differential diagnosis, Jan., 27-34
- Alzheimer's (see Alzheimer's disease)
aphasia and, progressive, Jan., 33
cobalamin deficiency and, Jan., 31
criteria for, NINCDS-ADRDA, Jan., 17-18
defining, Jan., 16-18
degenerative, Jan., 32-34
diagnostic evaluation, Jan., 24
drug toxicity causing, Jan., 27-28
endocrinopathies and, Jan., 31-32
frontal lobe, Jan., 33

- HIV
 after didanosine, Oct., 712
 after zidovudine, Oct., 709
 in Huntington's disease, Jan.,
 33-34
 hydrocephalic, symptomatic, Jan.,
 30
 in Korsakoff's syndrome, Jan.,
 30-31
 multi-infarct, Jan., 29
 in Parkinson's disease, Jan.,
 32-33
 in Pick's disease, Jan., 33
 potentially treatable, Jan., 27-32
 recognizing, Jan., 16-18
 vascular, Jan., 29-30
 vasculitis and, Jan., 32
- Dementing conditions: potentially treatable, Jan., 31-32
- Demographic data: for multiple organ failure syndrome, Dec., 860
- Dental
 extraction, DDAVP and gray platelet syndrome, Aug., 607
 procedures, antifibrinolytics after, Aug., 622
- Deoxydidehydrothymidine: in AIDS, Oct., 715
- L-Deprenyl: in depression in Alzheimer's disease, Jan., 38
- Depression in Alzheimer's disease, Jan., 21
 management, Jan., 38
- Dermatologic manifestations: of HIV infection, Sept., 671
- Desmopressin acetate (see DDAVP)
- Detrusor
 hyperactivity with impaired bladder contractility causing incontinence, in elderly, Feb., 98-99
 hyperreflexia causing urge incontinence, in elderly, Feb., 98
 instability causing urge incontinence, in elderly, Feb., 98
- d4T: in AIDS, Oct., 715
- Diabetes mellitus
 drug therapy in hypertension and, Nov., 822-824
- nephropathy in, enalapril or metoprolol in, Nov., 824
- Dialysis
 effect on bleeding tendency in uremic patients, Aug., 615
 hemodialysis in multiple organ failure syndrome, Dec., 860
 peritoneal, and pleural effusions, May, 290
 pleural effusions and, May, 322
- Diapers: adult, for geriatric urinary incontinence, Feb., 120
- Diaphragmatic hernia: and pleural effusion, May, 316
- Diastolic function: echocardiography of, June, 446-447
- Dicloazuril: in cryptosporidiosis in AIDS, Oct., 729
- Didanosine in AIDS, Oct., 711-714
 clinical experience, Oct., 712-713
 mechanism of action, Oct., 711
 pharmacology, Oct., 711-712
 resistance, Oct., 713-714
 toxicity, Oct., 713
- Dideoxycytidine in AIDS, Oct., 714-715
 clinical experience, Oct., 714-715
 mechanism of action, Oct., 714
 pharmacology, Oct., 714
 resistance, Oct., 715
 toxicity, Oct., 715
- 2',3'-Dideoxyinosine (see Didanosine)
- Dipyridamole
 /aspirin in polycythemia vera, Mar., 191
 /thallium myocardial perfusion imaging, June, 462-463
- Directives: advance, for Alzheimer's patients, Jan., 36-37
- Diuretics
 dosage variation, effects on blood pressure, blood chemistries, and lipids, Nov., 815
 in hypertension
 in diabetics, Nov., 823
 in elderly, Nov., 812-813, 822
 as initial therapy, Nov., 814-815
- Dizziness: in polycythemia vera, Mar., 171

- DNA probes: in unknown primary malignancy, Apr., 243
- Doppler echocardiography (*see* Echocardiography, Doppler)
- Down's syndrome: Alzheimer's disease in, Jan., 26-27
- Doxorubicin cardiotoxicity: endomyocardial biopsy in, June, 488
- Doxycycline: in malignant pleural effusions, May, 294
- Driving: and Alzheimer's disease, Jan., 37
- Drugs**
- in Alzheimer's disease, Jan., 49
 - antihypertensive (*see Drug, therapy in hypertension below*)
 - antiinflammatory (*see Antiinflammatory agents*)
 - effect on urinary continence, Feb., 96
 - induced lupus pleuritis, May, 318
 - interfering, causing resistant hypertension, Nov., 821
 - platelet dysfunction due to, Aug., 609-614
 - reactions causing pleural effusions, May, 319
 - therapy in hypertension, Nov., 809-826
 - clinical trial results, Nov., 810-812
 - costs, Nov., 825-826
 - in diabetics, Nov., 822-824
 - in elderly, Nov., 821-822, 823
 - in elderly, results, Nov., 812-814
 - exercise and, Nov., 805
 - individualizing, Nov., 815-816, 817
 - initial therapy, choice of, Nov., 814-815
 - renovascular, Nov., 819-821
 - resistant, Nov., 818-821
 - second choices, Nov., 816-818
 - sleep apnea and, Nov., 824-825
 - special problems, Nov., 821-825
 - subsequent choices, Nov., 816-818
- therapy in urinary incontinence, geriatric, Feb., 127-131
- mixed, Feb., 130-131
- overflow, Feb., 131
- stress, Feb., 130
- urge, Feb., 127-128
- toxicity causing dementia, Jan., 27-28
- use, IV, and HIV transmission, Sept., 661-662
- Dyslipidemias: and hypertension, Nov., 788-790
- Dyspnea**
- abnormal, as end point of exercise testing, June, 413
 - in cardiac evaluation, June, 357-358
 - in polycythemia vera, Mar., 171
- Dysproteinemias: platelet dysfunction in, Aug., 617

E

- Ebstein's anomaly: echocardiography in, June, 439
- ECG (*see* Electrocardiogram)
- Echinococcosis: pleural, May, 310
- Echocardiography, June, 417-455
- of aortic valve, bicuspid, June, 454
 - of atrial enlargement, June, 450
 - of cardiac masses, June, 451-453
 - of cardiac tumors, June, 451-452
 - of chamber enlargement and hypertrophy, June, 447-450
 - of diastolic function, June, 446-447
- Doppler, June, 428-430
- color-flow, June, 429-430
 - continuous-wave, June, 429
 - principles of Doppler signal measurement, June, 428-429
 - pulsed-wave, June, 429
- in endocarditis, infective, June, 440-441
- for functional assessment, June, 441-451
- in heart disease
- congenital, June, 453-454
 - valvular, June, 430-431
- limitations, technical, June, 430

- in mitral valve prolapse, June, 436
M-mode, June, 419-422
at level of aortic valve, June, 423
at level of mitral valve, June, 422
at level of papillary muscles, June, 421
of myxoma, June, 451
in pericardial disease, June, 454-455
in pericardial effusion, June, 454, 455
in pericarditis, constrictive, June, 454-455
in regurgitant lesions, June, 434-440
in regurgitation
aortic, June, 437, 438
mitral, June, 435-437
tricuspid, June, 437-440
of septal defect, atrial and ventricular, June, 453-454
in specific disease states, June, 430-455
in stenosis
aortic, June, 433-434
mitral, June, 431-433
in stenotic lesions, June, 431-434
stress, June, 450-451
of systolic function, June, 441-446
left ventricular, June, 442-444
left ventricular, in cardiomyopathy, dilated, June, 443-444
left ventricular, in ischemic heart disease, June, 442-443
right ventricular, June, 445-446
in tamponade, cardiac, June, 454
of thrombi, atrial and ventricular, June, 452-453
transesophageal, June, 425-428
two-dimensional, June, 422-425
apical four-chamber view, June, 424-425, 427
parasternal long-axis view, June, 423, 424, 425
parasternal short-axis view, June, 423-424, 426
subcostal views, June, 425
suprasternal view, June, 425
of ventricular dilatation
left, June, 447
right, June, 447-448
of ventricular hypertrophy
left, June, 448-450
right, June, 450
Edema
peripheral, in cardiac evaluation, June, 379-380
pulmonary, on chest radiography, June, 404-405
after resuscitation, Dec., 866-867
Education: low, and risk of Alzheimer's disease, Jan., 14
Effusion
parapneumonic (see Parapneumonic effusions and bacterial infections of pleural space)
pericardial (see Pericardial, effusion)
pleural (see Pleural effusion)
Eicosapentanoate: effect on platelet function, Aug., 614
Elastic forces: of lung and chest wall at resting level in mechanical analogue, July, 527
Elastic properties, July, 521-531
Elderly
bacteruria in, Feb., 90-91
treatment, Feb., 91-92
DDAVP in, Aug., 621
hypertension in, drug therapy for, Nov., 821-822, 823
results of trials, Nov., 812-814
incontinence in, urinary (see Incontinence, urinary, geriatric)
Electrical stimulators: in geriatric urinary incontinence, Feb., 133-134
Electrocardiogram, June, 380-397
in atrial enlargement, June, 389-390
left, June, 389-390
right, June, 390
in atrial tachycardia, multifocal, June, 392
axis, June, 383-384
in chamber enlargement, June, 387-392

- Electrocardiogram (cont.)**
- in cor pulmonale, June, 390–392
 - acute, June, 390
 - chronic, June, 391
 - exercise, ST segment on abnormalities in, June, 413–414
 - false positive responses, June, 414
 - ischemic changes, June, 413–414
 - lead(s)
 - limb, standard, June, 381–382
 - precordial, unipolar, June, 382–383
 - system, standard 12-lead, June, 381–384
 - in myocardial infarction, June, 394–397
 - non-Q wave, June, 397
 - Q wave, June, 394–397
- in myocardial ischemia, June, 392–397
- reversible, June, 393–394
 - normal, June, 380–387
 - normal sequence of activation, June, 384–387
- in pulmonary embolus, acute, June, 391
- vectors, June, 383–384
- in ventricular hypertrophy, left, June, 387–388
- Romhilt-Estes point system, June, 389
- Sokolow-Lyons criteria, June, 389
- in ventricular hypertrophy, right, June, 388–389
- Electromyography:** in geriatric urinary incontinence, Feb., 116
- Electron microscopy** in malignancy of unknown primary origin, Apr., 240–241
- transport in multiple organ failure syndrome, Dec., 876
- EMG:** in geriatric urinary incontinence, Feb., 116
- Emphysema:** compliance in, July, 523
- Empyema:** differentiated from lung abscess, May, 301
- Enalapril:** in diabetic nephropathy, Nov., 824
- Encephalitis:** toxoplasmic, in AIDS, Oct., 727
- Encephalopathy:** spongiform, Jan., 34
- Endocarditis, infective, echocardiography in**, June, 440–441 transesophageal, June, 428
- Endocrine disorders:** and polycythemia, Mar., 186
- Endocrinopathies:** and dementia, Jan., 31–32
- Endomyocardial biopsy**, June, 487–490
- Endoscopic variceal sclerotherapy:** pleural effusions after, May, 316
- Endothelial cells:** in multiple organ failure syndrome, Dec., 875–876
- Endotoxin:** antibodies against, in treatment of multiple organ failure syndrome, Dec., 884
- Enema:** barium, in unknown primary malignancy, Apr., 229
- Energy** consumption during exercise, July, 567 expenditure in multiple organ failure syndrome, Dec., 867–869 supply/demand ratio impairment during exercise, July, 571
- Environmental manipulation:** in geriatric urinary incontinence, Feb., 119–120
- Enzyme** immunoassay in HIV diagnosis, Sept., 672–673 inhibitors, angiotensin-converting, in hypertension in diabetics, Nov., 823–824
- Eosinophil protein-induced storage pool deficiency:** platelet dysfunction in, Aug., 619
- Epidermal growth factor:** in breast cancer, Apr., 246

- Epigastric distress: in polycythemia vera, Mar., 171
 Epinephrine-induced platelet aggregation, Aug., 593-594
 Epsilon amino caproic acid: for platelet function disorders, Aug., 622
 Epstein-Barr virus infection: in AIDS, Oct., 735
 Epstein's syndrome, Aug., 602
 Ergotamine: causing pleural effusion, May, 319
 Erythroid colonies: in polycythemia vera, Mar., 168
 Erythrokinetic studies: in postpolycythemic myeloid metaplasia, Mar., 200
 Erythromelalgia: in polycythemia vera, Mar., 172
 Erythropoiesis control of, Mar., 167
 normal and pathological, Mar., 167
 Erythropoietin levels after zidovudine in AIDS, Oct., 710
 production increase causing secondary polycythemia appropriate, Mar., 185-186
 inappropriate, Mar., 186
 recombinant, in postpolycythemic myeloid metaplasia, Mar., 202
 Esophagitis: *Candida*, in AIDS, Oct., 740-741
 Esophagus perforation, pleural effusions after, May, 314-315
 ulcerations, zidovudine-induced, Oct., 710
 Estrogen
 /alpha agonist in geriatric stress urinary incontinence, Feb., 130
 conjugated
 in platelet function disorders, Aug., 621
 in uremic patients, Aug., 615
 decrease, effect on micturition, Feb., 87
 /imipramine in geriatric mixed urinary incontinence, Feb., 130-131
 replacement therapy, risks, Feb., 119
 Ethchlorvynol: causing pleural effusion, May, 319
 Examination abdominal, in cardiac evaluation, June, 379
 cardiac, June, 368-378
 chest, in cardiac evaluation, June, 378-379
 extremity, in cardiac evaluation, June, 379-380
 neurologic, in Alzheimer's disease, Jan., 22-23
 physical (see Physical examination)
 Exercise
 cardiorespiratory adaptation to, July, 566-571
 poor cooperation and, July, 571
 cardiovascular limitation during, July, 569-570
 ECG (see Electrocardiogram, exercise)
 energy consumption during, July, 567
 energy supply/demand ratio impairment during, July, 571
 first-pass nuclear cardiology studies during, June, 458
 gas exchange during, abnormal, July, 568-569
 handgrip, cardiac auscultation during, June, 378
 oxygen consumption during, July, 567
 pelvic muscle, for geriatric incontinence, Feb., 121
 physiology, cardiac, June, 411-415
 prediction equations for, July, 576
 pulmonary vascular disease and, July, 570-571
 respiratory quotient during, July, 570
 testing, June, 410-417
 arrhythmias induced by, June, 415

- blood pressure response during, abnormal**, June, 414
Bruce protocol, June, 415–416
complications, June, 416–417
end point(s), angina as, June, 413
end point(s), dyspnea as, abnormal, June, 413
end point(s), fatigue as, June, 413
end point(s), ischemic, June, 412–413
end point(s), normal, June, 412–413
physical findings during, abnormal, June, 415
treadmill, after myocardial infarction, June, 416
types, June, 415–416
thallium imaging, June, 461–462
ventilatory limitation during, July, 566–568
Expiration: forced, snapshot of forces acting in chest during, July, 544
Expiratory flow-volume relationships, July, 551
reserve volume, July, 527
Extragonadal germ cell tumor, Apr., 251
 immunocytochemical stain in, Apr., 236
Extrapyramidal signs: in Alzheimer's disease, Jan., 20, 22
Extremity examination: in cardiac evaluation, June, 379–380
- F**
- Fat: dietary, and hypertension**, Nov., 808
Fatigue
 as end point of exercise testing, June, 413
 respiratory muscle, July, 553
Fatty acids
 omega-3, in multiple organ failure syndrome, Dec., 886
 turnover after resuscitation, Dec., 870
α-Fetoprotein
 immunocytochemical stain for, in extragonadal germ cell tumor, Apr., 236
 in malignancy of unknown primary origin, Apr., 231–232
Fever
 after catheterization, chronic indwelling urinary, in elderly, Feb., 136
Mediterranean, familial, causing pleural disease, May, 318–319
 Q, causing pleural effusions, May, 312
Fibrinogen: and platelet aggregation, Aug., 596–597
Fibronectin receptor: on platelets, Aug., 591, 596–597
Fibrosis: pulmonary, compliance in, July, 523
Fish
 consumption, effect on platelet function, Aug., 614
 oils and hypertension, Nov., 808
566C80 in AIDS
 for *Pneumocystis carinii* disease, Oct., 723, 724
 for toxoplasmosis, Oct., 728
Flow cytometry: in exudative pleural effusions, May, 282
Flow resistance, July, 532–538
 (*See also Airway, resistance*)
 in asthma, July, 534
 estimated from forced vital capacity, July, 537
 in peripheral airways, July, 543
 measurement in body plethysmograph, July, 535
Flow-volume relationships
 expiratory, examples of, July, 551
 during forced vital capacity maneuver, July, 537
 inspiratory, July, 551–552
 examples of, July, 551
FLT: in AIDS, Oct., 715
Fluconazole in AIDS
 for candidiasis, Oct., 741
 for cryptococcosis, Oct., 742–743
Flucytosine: in cryptococcosis in AIDS, Oct., 742–743

- Fluid**
 management in multiple organ failure syndrome, Dec., 882
 pleural (see *Pleural, fluid*)
- 5-Fluorocytosine:** in pleural cryptococcosis, May, 308
- Fluorodeoxythymidine:** in AIDS, Oct., 715
- Fluoxetine:** weight gain and smoking cessation, Nov., 800
- Fontan procedure:** pleural effusion after, May, 291
- Forced expiration:** snapshot of forces acting in chest during July, 544
- Forced vital capacity:** July, 536–538
 flow resistance estimated from, July, 537
 maneuver, flow-volume relationship during, July, 537
- Forgetfulness:** benign senescent, Jan., 17
- Foscarnet in AIDS**
 for cytomegalovirus infection, Oct., 732–733
 for herpes simplex virus infection, Oct., 734
 for varicella-zoster virus infection, Oct., 735
- Fracture:** hip, and imipramine in geriatric urinary incontinence, Feb., 127
- Friction rub:** pericardial, June, 374, 377
- Frontal lobe dementia:** Jan., 33
- Functional residual capacity:** July, 527
- Fungus**
 Chinese black tree, causing platelet dysfunction, Aug., 613
 infections
 in AIDS, Oct., 740–744
 of pleural space, May, 307–309
- G**
- Gallium-67 scans:** in unknown primary malignancy, Apr., 229
- Gallop:** summation, June, 372
- Ganciclovir in AIDS**
 for cytomegalovirus infection, Oct., 732
 for leukoplakia, oral hairy, Oct., 735
- Garlic extracts:** causing platelet dysfunction, Aug., 613
- Garments:** absorbent, for geriatric urinary incontinence, Feb., 120
- Gas**
 diffusion, July, 559
 distribution, July, 544–546
 exchange, July, 553–559
 abnormal, during exercise, July, 568–569
 disturbances, July, 555
 prediction equations for, July, 576
 transport in blood, July, 559–564
- Gastric**
 biopsy, aspirin, and platelet dysfunction, Aug., 611
 cancer, CA 19-9 in, Apr., 234
- Gastrointestinal**
 radiography in unknown primary malignancy, Apr., 229
 tract disease
 cytomegalovirus, in AIDS, Oct., 731
 pleural effusions due to, May, 313–316
- Gaucher's disease:** platelet dysfunction in, Aug., 618
- Genes**
 for glycoprotein IIb and IIIa, Aug., 604
 heat shock, in multiple organ failure syndrome, Dec., 878
- Genetics**
 (See also *Cytogenetics*)
 of Alzheimer's disease, Jan., 26–27
- Geriatric** (see *Elderly*)
- Germ cell tumor**
 extragonadal, Apr., 251
 immunocytochemical stain in, Apr., 236
- gonadal, Apr., 251
- Gerstmann-Straussler-Scheinker disease:** Jan., 34

- Giardia lamblia** infection: in AIDS, Oct., 730
- Glanzmann thrombasthenia**, Aug., 603–605
- Glaucoma**: and oxybutynin in geriatric urinary incontinence, Feb., 127
- Glomerular filtration rate**: effect of enalapril or metoprolol in diabetic nephropathy on, Nov., 824
- Glucose**
intolerance and upper body obesity, Nov., 790
metabolism in multiple organ failure syndrome, Dec., 869–870
- Pleural fluid**, in pleural effusions exudative, May, 282
malignant, May, 293
- Glycolysis**: aerobic, in multiple organ failure syndrome, Dec., 867–869
- Glycoprotein**
Ia/Ila deficiency, Aug., 602–603
Ib, Aug., 591
Ib/IX
complex, Aug., 591
deficiency, Aug., 600–602
- Ic/Ila deficiency, Aug., 602–603
- IIb, gene for, Aug., 604
- IIIa, Aug., 591
complex and platelet aggregation, Aug., 596–597
deficiency, Aug., 603–605
- IIIa, gene for, Aug., 604
- Gonadal germ cell tumors**: of unknown primary origin, Apr., 251
- Gonadotropin**: human chorionic, in unknown primary malignancy, Apr., 232
- Gout**: in polycythemia vera, Mar., 182
- gp160: recombinant, in AIDS, Oct., 720
- Granulocytes**: in polycythemia vera, Mar., 177–178
- Granulovacuolar degeneration**: in Alzheimer's disease, Jan., 44
- Gray platelet syndrome**, Aug., 602, 606–607
- Greco syndrome**, Apr., 251–252
- Growth factor**
epidermal, in breast cancer, Apr., 246
- insulin-like, causing hypoglycemia in benign mesothelioma, May, 298
- nerve, in Alzheimer's disease, Jan., 48–49
- platelet-derived, Aug., 597
- Guardianship**: and Alzheimer's disease, Jan., 37
- Gut**
barrier functions, failure in multiple organ failure syndrome, Dec., 879
- decontamination, selective, in multiple organ failure syndrome, Dec., 879–880
- H**
- Habit training**: for geriatric urinary incontinence, Feb., 124–125
- Haemophilus influenzae** infections: in AIDS, Oct., 744
- Hairy**
cell leukemia, platelet dysfunction in, Aug., 618
- leukoplakia, oral, in AIDS, Oct., 735
- Haloperidol**: in Alzheimer's disease, Jan., 38–39
- Handgrip**: cardiac auscultation during, June, 378
- Harrington rod spinal fusion**: DDAVP in, Aug., 621
- HCG**: in unknown primary malignancy, Apr., 232
- Head trauma**: as risk factor in Alzheimer's disease, Jan., 15
- Headache**: in polycythemia vera, Mar., 170–171
- Health**
care workers, HIV transmission to, Sept., 665–667
- psychological, effect of geriatric urinary incontinence on, Feb., 82–83

- public health impact of Alzheimer's disease, Jan., 13-16
- Heart**
- appearance on chest radiography, normal (see Radiography, chest, cardiac appearance on, normal)
 - auscultation (see Auscultation, cardiac)
 - bypass (see Bypass, cardiac)
 - catheterization (see Catheterization, cardiac)
 - chamber
 - enlargement, ECG in, June, 387-392
 - enlargement, echocardiography, June, 447-450
 - enlargement, on radiography, chest, June, 399-402
 - hypertrophy, echocardiography, June, 447-450
 - disease
 - congenital, echocardiography in, June, 453-454
 - congenital, MRI in, June, 465
 - congenital, on radiography, chest, June, 405-409
 - coronary, deaths from, relation to cholesterol, blood pressure, and smoking, Nov., 789
 - coronary, fatal, effect of drug therapy in hypertension on, Nov., 811
 - ischemic, echocardiography of left ventricular systolic function in, June, 442-443
 - ischemic, MRI in, June, 464
 - valvular, cardiac catheterization in, June, 470-483
 - valvular, echocardiography in, June, 430-431
 - dysfunction in multiple organ failure syndrome, Dec., 863-864
 - evaluation, June, 355-503
 - abdominal examination in, June, 379
 - arterial pressures in, June, 365-368
 - arterial pulse in, June, 366-368
 - arterial pulse wave configuration in, abnormal, June, 367-368
 - arterial pulse wave configuration in, normal, June, 366-367
 - blood pressure measurement in, June, 365-366
 - cardiac catheterization in (see Catheterization, cardiac)
 - chest examination in, June, 378-379
 - chest pain in, June, 357-358
 - clubbing in, June, 380
 - cough in, June, 362
 - dyspnea in, June, 357-358
 - edema in, peripheral, June, 379-380
 - electrocardiogram in (see Electrocardiogram)
 - exercise testing in (see Exercise, testing)
 - extremity examination in, June, 379-380
 - hemoptysis in, June, 360-362
 - imaging in, magnetic resonance (see Magnetic resonance imaging, in cardiac evaluation)
 - imaging in, myocardial perfusion (see Myocardial, perfusion imaging)
 - physical examination in, June, 362-380
 - radiography in, chest, June, 397-410
 - symptoms in, June, 356-357
 - syncope in, June, 359-360
 - tissue perfusion in, June, 380
 - venous pressure(s) in, June, 362-365
 - venous pressure wave configuration in, abnormalities, June, 364-365
 - venous pressure wave configuration in, normal, June, 362-364
 - examination, June, 368-378
 - exercise physiology, June, 411-415
 - failure, congestive

- Heart (cont.)**
- early, on chest radiography, June, 403-404
 - pleural effusion due to (see Pleural effusion, heart failure causing, congestive)
 - radiography in, chest, June, 402-405
 - function assessment
 - by echocardiography, June, 441-451
 - by nuclear cardiology techniques, June, 456-459
 - masses, echocardiography, June, 451-453
 - murmurs (see Murmurs, cardiac)
 - palpation, June, 368-369
 - postcardiac injury syndrome causing pleural effusions, May, 320-321
 - sounds (see Sounds, heart)
 - tamponade (see Tamponade, cardiac)
 - tumors
 - echocardiography in, June, 451-452
 - echocardiography in, transesophageal, June, 428
 - MRI of, June, 465
 - Heat shock genes: in multiple organ failure syndrome, Dec., 878
 - Helical filaments: in Alzheimer's disease, Jan., 43-44
 - Hemangioma: cerebellar, and polycythemia, Mar., 186
 - Hematocrit
 - correlation between red cell mass and, Mar., 174
 - increased
 - and increased red cell mass in differential diagnosis of polycythemia vera, Mar., 184-188
 - and normal red cell mass in differential diagnosis of polycythemia vera, Mar., 183-184
 - Hematologic toxicity: of zidovudine, Oct., 709-710
 - Hematopoiesis: scheme of, Mar., 166
 - Hemochromatosis: endomyocardial biopsy in, June, 488
 - Hemodialysis: in multiple organ failure syndrome, Dec., 860
 - Hemodynamic assessment
 - of aortic regurgitation, June, 482
 - of mitral regurgitation, June, 479
 - Hemoglobin: congenital abnormal, causing polycythemia, Mar., 185
 - Hemoptysis: in cardiac evaluation, June, 360-362
 - Hemorrhage: pathological, in polycythemia vera, Mar., 172
 - Heparin: causing platelet dysfunction, Aug., 613
 - Hepatic
 - (See also Liver)
 - hydrothorax (see Hydrothorax, hepatic)
 - vein thrombosis and polycythemia vera, Mar., 171
 - Hepatitis B transmission: to health care workers, Sept., 666
 - Hepatobiliary cancer: CA 19-9 in, Apr., 234
 - Hepatomas: and polycythemia, Mar., 186
 - Hermansky-Pudlack syndrome, Aug., 608
 - Hernia: diaphragmatic, and pleural effusion, May, 316
 - Herpes
 - simplex virus infection in AIDS, Oct., 733-734
 - zoster and HIV infection, Sept., 671
 - Heterosexual HIV transmission, Sept., 659-660
 - Hexabrix: in diagnosis of pleural effusions after esophageal perforation, May, 315
 - Hip
 - fracture, and imipramine in geriatric urinary incontinence, Feb., 127
 - replacement, intermittent catheterization after, in elderly, Feb., 135
 - Hirano bodies: in Alzheimer's disease, Jan., 44

- Histamine**
inhaled, effect on airway resistance, July, 550
in polycythemia vera, Mar., 177
- Histoplasma capsulatum* infection:**
in AIDS, Oct., 743
- Histoplasmosis:** pleural, May, 308–309
- History:** in geriatric urinary incontinence evaluation, Feb., 101–102
- HIV,** Sept., 647–652
(*See also AIDS*)
antigen in HIV diagnosis, Sept., 675–676
diagnosis
enzyme immunoassay in, Sept., 672–673
HIV antigen in, Sept., 675–676
viral culture in, Sept., 677–678
Western blot in, Sept., 673–675
- infection**
clinical stages, Sept., 656
infections, malignancies, and neurologic syndromes associated with, Sept., 657
polymerase chain reaction for, Sept., 678–679
-1
replication, Sept., 651
structural characteristics, basic, Sept., 649
- testing,** Sept., 669, 672–679
- transmission,** Sept., 658–667
by blood products, Sept., 663–664
to health care workers, Sept., 665–667
by intravenous drug use, Sept., 661–662
perinatal, Sept., 662–663
sexual, Sept., 659–661
by transplantation, Sept., 664
- Hodgkin's disease:** in AIDS, Oct., 750
- Home** (*see Nursing home*)
- Homosexual men:** HIV transmission by, Sept., 659
- Hormone receptors:** in unknown primary malignancy, Apr., 241
- Hospice care:** in Alzheimer's disease, Jan., 36
- HTLV-I/II infection:** in AIDS, Oct., 736
- Human immunodeficiency virus** (*see HIV*)
- Human T cell lymphotropic virus-I/II infection:** in AIDS, Oct., 736
- Huntington's disease:** dementia in, Jan., 33–34
- Hyaluronic levels:** in pleural fluid, in malignant mesothelioma, May, 297
- Hydatid disease:** pleural, May, 310
- Hydergine:** in Alzheimer's disease, Jan., 49
- Hydrocephalic dementia:** symptomatic, Jan., 30
- Hydrochlorothiazide:** in hypertension, in elderly, Nov., 822
- Hydroergotoxine:** in Alzheimer's disease, Jan., 49
- Hydrolases:** acid, in platelet lysosomes, Aug., 598
- Hydronephrosis:** and polycythemia, Mar., 186
- Hydrothorax, hepatic,** May, 288–289
clinical manifestations, May, 289
diagnosis, May, 289
pathophysiology, May, 288–289
treatment, May, 289
- Hydroxynaphthoquinone 566C80** (*see 566C80*)
- Hydroxyurea**
in myeloid metaplasia, postpolycythemic, Mar., 202
in myeloproliferative disorders, Aug., 618
in polycythemia vera, Mar., 193–195
red cell volume increase after, Mar., 176
- Hypercholesterolemia:** and hypertension, Nov., 788–789
- Hypernephroma:** and polycythemia, Mar., 186
- Hyperreflexia:** detrusor, causing urge incontinence, in elderly, Feb., 98

- Hypertension, Nov., 783-838
 alcohol moderation in, Nov., 803
 caffeine and, Nov., 808-809
 calcium supplements in, Nov., 806
 coffee and, Nov., 808-809
 drug therapy in (see Drug, therapy in hypertension)
 dyslipidemias and, Nov., 788-790
 fat and, Nov., 808
 fish oils and, Nov., 808
 insulin resistance and, Nov., 790-792
 magnesium supplements in, Nov., 806
 management, Nov., 783-838
(See also therapy below)
 conclusion, Nov., 829-830
 obesity and, upper body, Nov., 790
 physical activity in, Nov., 804-805
 in polycythemia vera, Mar., 173
 potassium intake increase in, Nov., 805-806
 pulmonary, chest pain in, June, 359
 refractory, causes, Nov., 818
 renin activity and, plasma, Nov., 793-794
 renovascular
 clinical clues for, Nov., 820
 drug therapy in, Nov., 819-821
 screening tests for, Nov., 820
 resistant
 drug therapy in, Nov., 818-821
 interfering drugs causing, Nov., 821
 risk factors, alterable, assessment of, Nov., 788-795
 overall, Nov., 794
 smoking cessation and, Nov., 795, 798-799
 sodium restriction in, Nov., 800-803
 stress management in, Nov., 806-808
 therapy
(See also management above)
 blood pressure monitoring during, Nov., 786-787
 goal of, Nov., 826-829
 J-curve phenomenon and, Nov., 828, 829
- life-style modifications for (see Life-style modifications for treatment of hypertension)
 ventricular hypertrophy and, left, Nov., 792-793
 weight reduction in, Nov., 799-800
- Hyperthyroidism: and dementia, Jan., 31
- Hypertriglyceridemia
 in HIV infection, Sept., 672
 obesity and upper body, Nov., 790
- Hypertrophic cardiomyopathy: endomyocardial biopsy in, June, 487-488
- Hypertrophy
 chamber, echocardiography, June, 447-450
 ventricular, left
 ECG in (see Electrocardiogram, in ventricular hypertrophy, left)
 echocardiography, June, 448-450
 hypertension and, Nov., 792-793
 ventricular, right
 ECG in, June, 388-389
 echocardiography, June, 450
- Hypocholesterolemia: in HIV infection, Sept., 672
- Hypoglycemia: in benign mesothelioma due to insulin-like growth factor, May, 298
- Hypothyroidism: and dementia, Jan., 31
- Hypoventilation: alveolar, and polycythemia, Mar., 185
- Hypoxemia
 arterial, causing polycythemia, Mar., 185
 respiratory response to, July, 565

I

Imaging

- magnetic resonance (see Magnetic resonance imaging)
 in malignancy of unknown primary origin, Apr., 229

- myocardial perfusion (see Myocardial, perfusion imaging)
nuclear, principles, June, 456
radionuclide, in unknown primary malignancy, Apr., 229–230
sound wave, principles, June, 417–419
- Imipramine
in depression in Alzheimer's disease, Jan., 38
in incontinence, geriatric urinary mixed, Feb., 130–131
urge, Feb., 127
- Immune disorder: and acquired thrombasthenia, Aug., 605
- Immunoassay: enzyme, in HIV diagnosis, Sept., 672–673
- Immunoblastic lymphadenopathy: causing pleural disease, May, 319
- Immunocytochemistry
in germ cell tumor, extragonadal, Apr., 236
in malignancy of unknown primary origin, Apr., 235–240
screening panel of, Apr., 238–239
- Immunodeficiency syndrome, acquired (see AIDS)
virus, human (see HIV)
- Immunofluorescence: indirect, in HIV diagnosis, Sept., 675
- Immunologic studies: in exudative pleural effusions, May, 284
- Immunomodulators: in AIDS, Oct., 720
- Impulse, ventricular
left, apical, June, 368
right, June, 369
- Incontinence, urinary, geriatric, Feb., 77–149
absorbent pads and garments for, Feb., 120
acute form, Feb., 94–96
adverse effects, Feb., 82–83
artificial sphincter in, Feb., 133
behavioral therapies in (see Behavioral, therapies in geriatric urinary incontinence)
- catheter(s) in, Feb., 134–138
external, Feb., 134
indwelling, chronic, Feb., 135–138
- catheterization in, intermittent, Feb., 135
- clamps for, Feb., 132–133
- classification, clinical, Feb., 94–100
- costs, Feb., 83
- definition, Feb., 78–79
- devices for, Feb., 132–134
- diagnostic evaluation, Feb., 100–117
- bladder records in (see Bladder, records)
- clinical assessment in, initial, Feb., 101–112
- components of, Feb., 101
- criteria for referral, Feb., 112, 114–115
- cystometrogram in (see Cystometrogram)
- cystometry in, simple, Feb., 111
- cystourethroscopy in, Feb., 113
- electromyography in, Feb., 116
further, Feb., 113–117
history in, Feb., 101–102
laboratory studies in, Feb., 106
overview, Feb., 100–101
physical examination in, Feb., 103, 106
- radiography in, Feb., 113
- urethral pressure profile in, Feb., 116–117
- urodynamic testing in (see Urodynamic testing in geriatric urinary incontinence)
- uroflowmetry in, Feb., 116
- drug therapy in, Feb., 127–131
- electrical stimulators in, Feb., 133–134
- environmental manipulation in, Feb., 119–120
- functional, Feb., 99–100
definition and causes, Feb., 97
- general issues, Feb., 78–83
incidence, Feb., 80–81
mixed, Feb., 100
drug therapy in, Feb., 130–131

- Incontinence (*cont.*)
overflow, Feb., 99
 definition and causes, Feb., 97
 drug therapy in, Feb., 131
pathophysiologic considerations, Feb., 83-94
pathophysiology, basic, Feb., 93-94
persistent forms, Feb., 96-100
 definitions and causes, Feb., 97
pessaries in, Feb., 133
physiologic considerations, Feb., 83-94
prevalence, Feb., 80-81
prompted voiding protocol for,
 example, Feb., 126
requirements for, Feb., 92-93
reversible factors contributing to,
 Feb., 95
 treatment, Feb., 117-119
reversible form, Feb., 94-96
stress, Feb., 97-98
 definition and causes, Feb., 97
 drug therapy in, Feb., 130
surgery in, Feb., 131-132
treatment, Feb., 117-132
 nonspecific measures, Feb.,
 119-120
 overview, Feb., 117
unconscious, Feb., 98
urge, Feb., 98-99
 definition and causes, Feb., 97
 drug therapy in, Feb., 127-130
urinary tract abnormalities underlyng lower, Feb., 93
- Infarction
myocardial (*see* Myocardial, infarction)
pulmonary, causing hemoptysis
 in mitral stenosis, June, 361-362
- Infections
associated with AIDS and advanced HIV infection, Sept., 657
nosocomial, in multiple organ failure syndrome, Dec., 878-880
- Infectious complications: of AIDS, Oct., 720-745
- Infective endocarditis, echocardiography in, June, 440-441
transesophageal, June, 428
- Inflammatory disease, pelvic, and AIDS, Oct., 744-745
- myocarditis, endomyocardial biopsy in, June, 487
- response syndrome, systemic (*see* Systemic inflammatory response syndrome)
- Innervation: basic, of lower urinary tract, Feb., 85
- Insect transmission: of HIV, Sept., 665
- Insemination: artificial, HIV transmission by, Sept., 664
- Inspiratory capacity, July, 527
flow-volume relationship, July, 551-552
examples of, July, 551
reserve volume, July, 527
- Insulin
-like growth factor causing hypoglycemia in benign mesothelioma, May, 298
resistance
 factors in, Nov., 791
 hypertension and, Nov., 790-792
- Intensive care unit: multiple organ failure syndrome after, Dec., 886-887
- Interferon
-alpha
 in Kaposi's sarcoma in AIDS, Oct., 747
/zidovudine in AIDS, Oct., 716
-gamma levels in tuberculous pleural effusions, May, 285
in myeloid metaplasia, postpolycythemic, Mar., 202
in polycythemia vera, Mar., 196
- Interleukin-2: in metastatic melanoma, Apr., 245
- Intra-abdominal abscess: and pleural effusion, May, 315-316
- Intravenous drug use: and HIV transmission, Sept., 661-662

- Irradiation
in Kaposi's sarcoma in AIDS, Oct., 747-748
spleen, in postpolycythemic myeloid metaplasia, Mar., 204
- Ischemia, myocardial, ECG in, June, 392-397
reversible, June, 393-394
- Ischemic
end point of exercise testing, June, 412-413
heart disease (see Heart, disease, ischemic)
ST segment changes during exercise testing, June, 413-414
- Isoniazid
in pleural effusions, tuberculous, May, 306
in tuberculosis, in AIDS, Oct., 739
- Isonitrile myocardial perfusion imaging, June, 463
- Isosporiasis: in AIDS, Oct., 729-730
- Itraconazole in AIDS
for aspergillosis, Oct., 744
for candidiasis, Oct., 741
for coccidioidomycosis, Oct., 744
for histoplasmosis, Oct., 743
- J**
- J-curve phenomenon: and hypertension therapy, Nov., 828, 829
- Joint symptoms: in polycythemia vera, Mar., 171
- Jugular venous pressure tracing: in cardiac evaluation, June, 364
- K**
- Kaposi's sarcoma in AIDS, Oct., 746-748
pleural effusions and, May, 311
- Kegel exercises: for geriatric incontinence, Feb., 121
- Ketoconazole
in blastomycosis, pleural, May, 307
in candidiasis in AIDS, Oct., 741
in histoplasmosis in AIDS, Oct., 743
- Ketones: plasma, after resuscitation, Dec., 870
- Kidney
cysts and polycythemia, Mar., 186
disease, polycystic, and polycythemia, Mar., 186
tumors and polycythemia, Mar., 186
- Killer cells: lymphokine-activated, in metastatic melanoma, Apr., 245
- Klinefelter's syndrome: and mediastinal germ cell tumors, Apr., 251
- Korsakoff's syndrome, Jan., 30-31
- Kuru, Jan., 34
- Kussmaul's sign, June, 365
- L**
- Laboratory
findings in polycythemia vera (see Polycythemia, vera, laboratory findings in)
studies in geriatric urinary incontinence, Feb., 106
tests in pleural effusions, costs of, May, 279-280
- Lactate production: after resuscitation, Dec., 867-869
- Lactic dehydrogenase
pleural fluid, in exudative pleural effusions, May, 283
in polycythemia vera, Mar., 182
- Laminin receptor: on platelets, Aug., 591
- Lavage: bronchoalveolar, in diagnosis of *Pneumocystis carinii* pneumonia in AIDS, Oct., 722
- LDH (see Lactic dehydrogenase)
- Leads, ECG (see Electrocardiogram, leads)
- Legionella infections: in AIDS, Oct., 745
- Leishmania donovani* infection: in AIDS, Oct., 730
- Lentivirinae, Sept., 647-648
- Letrazuril: in cryptosporidiosis in AIDS, Oct., 729

- Leucovorin in AIDS
for *Pneumocystis carinii* disease,
Oct., 723
for toxoplasmosis, Oct., 727-728
- Leukemia
acute, after splenectomy in post-polycythemic myeloid metaplasia, Mar., 201
hairy cell, platelet dysfunction in, Aug., 618
myeloid
platelet dysfunction in, Aug., 618
in polycythemia vera, Mar., 198
- Leukocyte
alkaline phosphatase in polycythemia vera, Mar., 177, 178
count
in pleural effusions, exudative, May, 281-282
in polycythemia vera, Mar., 177
differential in exudative pleural effusions, May, 281-282
- Leukoencephalopathy: multifocal, in AIDS, Oct., 736
- Leukopenia: zidovudine-induced, Oct., 710
- Leukoplakia: oral hairy, in AIDS, Oct., 735
- Life-style modifications for treatment of hypertension, Nov., 795-809
combination therapies, Nov., 796-797
conclusion, Nov., 809
individual, Nov., 797-798
- Light microscopy: in malignancy of unknown primary origin, Apr., 235
- Linkage analysis: in Huntington's disease, Jan., 34
- Lipids: effects of diuretic dosage on, Nov., 815
- Listeria* infections: in AIDS, Oct., 745
- Lithium: in Alzheimer's disease, Jan., 39
- Liver
(See also Hepatic)
disease, platelet dysfunction in, Aug., 616
- palpable, in polycythemia vera, Mar., 173
scans in unknown primary malignancy, Apr., 229
- Loxepine: in Alzheimer's disease, Jan., 38
L-697, 639 and L-697, 661: in AIDS, Oct., 715-716
- Lung
(See also Pulmonary)
abscess differentiated from emphyema, May, 301
capacity
closing, July, 548
total, subdivisions of lung volume as proportion of, July, 526
compliance, July, 522
dynamic, effect of increase in respiratory frequency on, July, 548
in emphysema, July, 523
in fibrosis, July, 523
frequency dependence of, July, 546-548
- disease
chronic, pulsus paradoxus in, June, 368
mixed, lung volume in, July, 530
mixed, volume-pressure relationship in, July, 531
obstructive (see below)
polycythemia and, Mar., 185
restrictive (see below)
- disease, obstructive
lung volume in, July, 530
ventilatory function disturbances in, July, 538
- ventilatory pattern in, July, 539, 540, 541, 542
- disease, restrictive
exercise in, relationship between respiratory rate and tidal volume during, July, 568
lung volume in, July, 530
ventilatory function disturbances in, July, 538

- ventilatory pattern in, July, 538-539
 volume-pressure curve in,
 static, July, 525
 trapped, causing pleural effusion,
 May, 323
 unit disturbances, peripheral,
 July, 541-548
 volume, July, 526-531
 calculation, physical method
 of, July, 529
 closing, July, 548
 -flow relationships (*see* Flow-
 volume relationships)
 in healthy vs. ill individuals,
 July, 530
 prediction equations for, July,
 575
 -pressure curve, static, in air-
 flow limitation, July, 525
 -pressure curve, static, in
 healthy individual, July, 524
 -pressure curve, static, in re-
 strictive disorder, July, 525
 -pressure relationship, effect of
 localized airway obstruction
 on, July, 547
 -pressure relationship in mixed
 disorder, July, 531
 relationship between airway
 conductance and, July,
 536
 relationship between airway
 resistance and, July, 536
 subdivisions, July, 526
 Lupus pleuritis, May, 317-318
 Lymphadenopathy
 in HIV infection, Sept., 671
 immunoblastic, causing pleural
 disease, May, 319
 Lymphatic clearance: of pleural
 fluid, May, 275
 Lymphocytes
 B, in HIV infection, Sept., 672
 T (see T cells)
 Lymphokine-activated killer cells: in
 metastatic melanoma, Apr.,
 245
 Lymphoma
 large-cell, Apr., 250-251
 non-Hodgkin's, in AIDS, Oct.,
 748-749
 Epstein-Barr virus-associated,
 Oct., 735
 after zidovudine, Oct., 710
 Lymphotrophic virus infection: I/II,
 human T cell, in AIDS, Oct.,
 736
 Lysosomes: platelet, Aug., 598
 Lysozyme levels: in polycythemia
 vera, Mar., 177
- M**
- Macrophages
 in AIDS, Sept., 654-655
 in multiple organ failure syn-
 drome, Dec., 874-875
 Magnesium supplements: in hyper-
 tension, Nov., 806
 Magnetic resonance imaging
 in Alzheimer's disease, Jan., 25
 in aortic disease, June, 465
 of bone marrow in polycythemia
 vera, Mar., 180
 in cardiac evaluation, June, 463-
 465
 principles, June, 464
 in specific disease states, June,
 464
 in heart disease
 congenital, June, 465
 ischemic, June, 464
 of heart tumors, June, 465
 in malignancy of unknown origin,
 Apr., 230
 in pericardial disease, June, 464-
 465
 in Pick's disease, Jan., 33
 in toxoplasmic encephalitis in
 AIDS, Oct., 727
 Malaria: and HIV, Sept., 665
 Malignancy
 (*See also* specific malignancy)
 associated with AIDS and ad-
 vanced HIV infection, Sept.,
 657
 of undetermined primary origin
 (*see* Unknown primary malig-
 nancy)

- Malnutrition: in multiple organ failure syndrome, treatment of, Dec., 882-883
- Mammography: in unknown primary malignancy, Apr., 229
- Mantoux tuberculin skin testing: in AIDS, Oct., 739
- Marrow (see Bone, marrow)
- Maximum voluntary ventilation, July, 538
- May-Hegglin anomaly, Aug., 602
- Mediastinal germ cell tumors: and Klinefelter's syndrome, Apr., 251
- Medications (see Drugs)
- Mediterranean fever: familial, causing pleural disease, May, 318-319
- Megakaryocytes: in polycythemia vera, Mar., 181
- Meigs syndrome: pleural effusion in, May, 323-324
- Melanoma: metastatic, interleukin-2 and lymphokine-activated killer cells in, Apr., 245
- Melphalan: in polycythemia vera, Mar., 195
- Memory impairment: age-associated, Jan., 17
- Mental status: in HIV dementia after zidovudine, Oct., 709
- Mesothelioma
ovarian, Apr., 253-254
peritoneal, Apr., 252-253
pleural, benign, May, 297-298
clinical manifestations, May, 298
diagnosis, May, 298
treatment, May, 298
- pleural, malignant, May, 296-297
clinical manifestations, May, 296-297
diagnosis, May, 297
treatment, May, 297
- Metabolic acid-base disturbances, July, 563-564
- Metabolism: postresuscitative, Dec., 865-872
- Metaplasia (see Myeloid, metaplasia)
- Metastases
pathophysiology, Apr., 224-227
prostate cancer, immunocytochemical stain for prostate-specific antigen in, Apr., 237
- Metastatic
cascade, tumor-host interactions during, Apr., 224
involvement in unknown primary malignancy, Apr., 223
melanoma, lymphokine-activated killer cells and interleukin-2 in, Apr., 245
- Metformin: in hypertension in diabetics, Nov., 824
- Methacholine: inhaled, effect on airway resistance, July, 550
- Methylphenidate: in depression in Alzheimer's disease, Jan., 38
- Methysergide: causing pleural effusion, May, 319
- Metoprolol: in diabetic nephropathy, Nov., 824
- Metronidazole
in isosporiasis in AIDS, Oct., 730
pleural effusion due to, May, 319
- MIBI myocardial perfusion imaging: technetium-99m, June, 463
- Microcirculation: peripheral, oxygen extraction failure in, in multiple organ failure syndrome, Dec., 865
- Microscopy in malignancy of unknown primary origin
electron, Apr., 240-241
light, Apr., 235
- Microsporidia infections: in AIDS, Oct., 730
- Micturition (see Urination)
- Mini-Mental Status Examination: in Alzheimer's disease, Jan., 22
- Minocycline in pleural effusions in congestive heart failure, May, 288
malignant, May, 294, 295
- Mithramycin: causing platelet dysfunction, Aug., 613
- Mitochondrial damage: after zidovudine, Oct., 710

- Mitomycin: causing pleural effusion, May, 319
- Mitoxantrone: in malignant pleural effusions, May, 295
- Mitral regurgitation, June, 476-481
catheterization in, June, 477-479
catheterization in, for prognosis assessment, June, 479-481
echocardiography in, June, 435-437
hemodynamic assessment, June, 479
pathophysiology, June, 476-477
- stenosis (see Stenosis, mitral)
valve prolapse, echocardiography in, June, 436
- MODS (see Multiple organ dysfunction syndrome)
- Molecular diagnostic methods: in unknown primary malignancy, Apr., 243
- Monitoring (see Blood, pressure, monitoring)
- Monoclonal antibody therapy: in multiple organ failure syndrome, Dec., 884-885
- Monocytes: in AIDS, Sept., 654-655
- Montreal platelet syndrome, Aug., 602
- Mortality (see Death)
- Moxalactam: and platelet function, Aug., 612
- MRI (see Magnetic resonance imaging)
- Multiple organ dysfunction syndrome
(See also Multiple organ failure syndrome)
discussion of term, Dec., 856
progressive, characteristics of, Dec., 862
- Multiple organ failure syndrome, Dec., 855-895
arginine in, Dec., 885
clinical characterization, Dec., 856-861
- cytokine effects, Dec., 866
- demographic data, Dec., 860
- development, prediction of, Dec., 861
- discriminators of survival, Dec., 860, 861
- fatty acids in, ω-3, Dec., 886
- glycolysis in, aerobic, Dec., 868
- historical perspective, Dec., 855-856
- after intensive care unit, Dec., 886-887
- nosocomial infections in, Dec., 878-880
- pathogenesis, Dec., 872-878
- pathways, Dec., 858
- postresuscitative metabolism, Dec., 865-872
- postresuscitative physiologic response, Dec., 861-865
- presentation, most common, Dec., 859
- ribonucleic acid in, Dec., 885
- summary, Dec., 887-888
- therapy
current approach to, Dec., 880-883
new approaches to, Dec., 883-886
- Muramidase: in polycythemia vera, Mar., 177
- Murmur(s), cardiac, June, 372-378
characteristics, June, 372, 374, 375
- diastolic, characteristics, June, 376
- intensity, June, 373-374
- location, June, 374
- quality, June, 374
- radiation, June, 374
- response to maneuvers, June, 374, 377-378
- shape, June, 373
- systolic, characteristics, June, 375
- timing, June, 372-373
- Muscle
pelvic, exercises, for geriatric incontinence, Feb., 121
- respiratory (see Respiratory, muscle)

- Mycobacterial infections:** in AIDS, Oct., 736-740
- Mycobacterium**
- avium* complex disease in AIDS, Oct., 736-738
 - kansasii* infection in AIDS, Oct., 739-740
 - tuberculosis* infection in AIDS, Oct., 738-739
- Myelodysplasia:** Bernard-Soulier-like platelets in, in children, Aug., 602
- Myeloid**
- leukemia (see Leukemia, myeloid) metaplasia, agnogenic, and age, Mar., 170
- metaplasia, postpolycythemic**
- anemia in (see Anemia, in myeloid metaplasia, postpolycythemic)
 - biopsy in, bone marrow, Mar., 200
 - clinical course, Mar., 198-199
 - erythrokinetic studies in, Mar., 200
 - etiology, Mar., 169-170
 - pathogenesis, Mar., 169-170
 - spleen enlargement in, therapy, Mar., 203-204
 - therapy, Mar., 199-204
 - thrombocytopenia in, therapy, Mar., 203
- Myeloma:** multiple, and acquired thrombasthenia, Aug., 605
- Myeloproliferative disorders:** platelet dysfunction in, Aug., 617-618
- Myelosuppressive therapy:** in polycythemia vera, Mar., 193-196
- Myocardial**
- disease, cardiac catheterization in, June, 483-487
 - infarction
- ECG in (see Electrocardiogram, in myocardial infarction)
 - MRI in, June, 464
 - treadmill testing after, June, 416
- ischemia, ECG in, June, 392-397
 - reversible, June, 393-394
- perfusion imaging**, June, 459-463
- isonitrile, June, 463
 - thallium (see Thallium imaging)
- Myocarditis:** inflammatory, endomyocardial biopsy in, June, 487
- Myoclonus:** in Alzheimer's disease, Jan., 23
- Myomas:** uterine, and polycythemia, Mar., 186
- Myopathy:** zidovudine-induced, Oct., 710
- Myxedema:** and pleural effusion, May, 291
- Myxoma:** echocardiography, June, 451

N

Nail: yellow nail syndrome, pleural effusion in, May, 322

Needle

biopsy (see Biopsy, pleural, needle sticks and HIV, Sept., 665-666)

Neoplastic complications: of AIDS, Oct., 720-721, 746-750

Nephropathy: diabetic, enalapril or metoprolol in, Nov., 824

Nephrotic syndrome: pleural effusions in, May, 290

Nerve growth factor: in Alzheimer's disease, Jan., 48-49

Nervous system: central, lymphoma, in AIDS, Oct., 748-749

Neuritic plaques: in Alzheimer's disease, Jan., 41-43

Neurochemical anatomy: in Alzheimer's disease, Jan., 45-47

Neuroendocrine carcinoma: poorly differentiated, Apr., 251-252

Neurofibrillary tangles: in Alzheimer's disease, Jan., 43-44

Neurohumoral system: in multiple organ failure syndrome, Dec., 874

Neuroleptics

for aggressiveness in Alzheimer's disease, Jan., 38-39

sedating, for sleep/wake disturbances in Alzheimer's disease, Jan., 38

Neurologic

- examination in Alzheimer's disease, Jan., 22-23
- syndromes associated with advanced HIV infection and AIDS, Sept., 657
- Neuropathy, peripheral**
 - didanosine-induced, Oct., 713
 - dideoxycytidine-induced, Oct., 715
- Neuropsychological performance tests:** in dementia, Jan., 17, 22
- Neurotransmitters, aminergic, in Alzheimer's disease,** Jan., 46
- cognitive therapy directed toward, Jan., 49
- Newborn:** polymerase chain reaction for HIV infection in, Sept., 679
- Nimodipine:** in Alzheimer's disease, Jan., 49
- NINCDS-ADRDA criteria**
 - for Alzheimer's disease, Jan., 18
 - for dementia, Jan., 17-18
- Nitrofurantoin:** causing pleural effusion, May, 319
- Nitroglycerin:** causing platelet dysfunction, Aug., 613
- Nocardia infections:** in AIDS, Oct., 745
- Nocturia:** in elderly, Feb., 90
- Nootropics:** in Alzheimer's disease, Jan., 49
- Nosocomial infections:** in multiple organ failure syndrome, Dec., 878-880
- Novantrone:** in malignant pleural effusions, May, 295
- Nuclear**
 - cardiology** (see Cardiology, nuclear)
 - magnetic resonance imaging** (see Magnetic resonance imaging)
- Nursing home**
 - incontinence in, urinary, Feb., 80
 - special care units for Alzheimer's patients, Jan., 36
- Nutritional support:** in multiple organ failure syndrome, Dec., 882-883

O

- Obesity:** upper body, related to glucose intolerance, hypertriglyceridemia, and hypertension, Nov., 790
- Oils:** fish, and hypertension, Nov., 808
- Onion extracts:** causing platelet dysfunction, Aug., 613
- Operating room:** HIV transmission in, Sept., 666
- Opportunistic infections:** in AIDS, treatment regimens, Oct., 724-725
- Oral**
 - hairy leukoplakia in AIDS, Oct., 735
 - thrush in AIDS, Oct., 740
- Organ**
 - multiple organ dysfunction syndrome (see Multiple organ dysfunction syndrome)
 - multiple organ failure syndrome (see Multiple organ failure syndrome)
- Orogenital transmission:** of HIV, Sept., 659
- Orthopedic surgery:** aspirin and platelet dysfunction, Aug., 611
- Ovarian**
 - cancer, CA-125 in, Apr., 233
 - mesothelioma, Apr., 253-254
- Oxybutynin** in geriatric urinary incontinence
 - mixed, Feb., 130
 - urge, Feb., 127
- Oxygen**
 - consumption
 - demand in multiple organ failure syndrome, Dec., 863
 - during exercise, July, 567
 - flow-dependent, in multiple organ failure syndrome, Dec., 864
 - delivery, defective, causing polycythemia, Mar., 185-186
 - extraction failure in peripheral microcirculation in multiple organ failure syndrome, Dec., 865

transport in blood, July, 560-561
Oxyhemoglobin dissociation curve,
July, 560

P

P(A-a)O₂: abnormal, mechanisms
underlying, July, 556
Pads: absorbent, for geriatric uri-
nary incontinence, Feb., 120
Pain: chest, in cardiac evaluation,
June, 358-359
Palpation: cardiac, June, 368-369
Pancreas
cancer, CA 19-9 in, Apr., 234
disease differentiated from exu-
dative pleural effusions, May,
283
pleural effusion, chronic, May,
314
Pancreatitis
acute, pleural effusions in, May,
313
didanosine-induced, Oct., 713
Papillary stenosis: with sclerosing
cholangitis due to cytomegalo-
virus in AIDS, Oct., 731
Papillomavirus infection: in AIDS,
Sept., 671; Oct., 735-736
Papovavirus infection: in AIDS, Oct.,
736
Paragonimiasis: pleural, May, 310
Parapneumonic effusions and bac-
terial infections of pleural
space, May, 298-304
bacteriology, May, 299-300
chest tube drainage in
closed, May, 302-303
open, May, 304
clinical manifestations, May, 300
decortication in, May, 303-304
diagnosis, May, 300-301
loculated, May, 301
pathogenesis, May, 298
thrombolytic therapy in, May, 303
treatment, May, 301-304
Paromomycin: in cryptosporidiosis
in AIDS, Oct., 729
Parasitic infections: of pleural
space, May, 309-310

Paresthesias: in polycythemia vera,
Mar., 171
Parietal pleurectomy: in yellow nail
syndrome, May, 322
Parkinson's disease: dementia in,
Jan., 32-33
PCO₂: pleural fluid, in exudative
pleural effusions, May, 284
Pelvic
CT scans in unknown primary
malignancy, Apr., 228
inflammatory disease and AIDS,
Oct., 744-745
muscle exercises for geriatric in-
continence, Feb., 121
Penile clamp: for geriatric urinary
incontinence, Feb., 132-133
Pentamidine
aerosolized, in *Pneumocystis cari-*
nii disease in AIDS, Oct., 723
prophylactic, Oct., 726
parenteral, in *Pneumocystis cari-*
nii disease in AIDS, Oct., 722,
723
Peptic ulcer: and polycythemia
vera, Mar., 171
Perfusion
distribution, July, 557
imaging, myocardial (see Myocar-
dial, perfusion imaging)
tissue, in cardiac evaluation,
June, 380
venous-admixture-like, July, 557-
558
/ventilation mismatch, July, 557-
558
Pericardial
disease
cardiac catheterization in,
June, 483-487
echocardiography in, June,
454-455
MRI in, June, 464-465
pleural effusion due to, May,
321
on radiography, chest, June,
409-410
effusion
echocardiography in, June, 454,
455

- on radiography, chest, June, 409-410
- friction rub, June, 374, 377
- Pericardiocentesis: cardiac catheterization in cardiac tamponade after, June, 489
- Pericarditis, constrictive
cardiac catheterization in, June, 483-486
- echocardiography in, June, 454-455
- on radiography, chest, June, 410, 411
- Perinatal transmission of HIV, Sept., 662-663
- Peritoneal
dialysis and pleural effusions, May, 290
- mesothelioma, Apr., 252-253
- Periurethral
abscess after chronic indwelling catheter, in elderly, Feb., 136
- Teflon injections in geriatric urinary incontinence, Feb., 132
- Pessaries: in geriatric urinary incontinence, Feb., 133
- PET (*see* Tomography, positron emission)
- pH, pleural fluid, in pleural effusions
exudative, May, 284
malignant, May, 293
- Pharmacologic
manipulation in diagnosis of Huntington's disease, Jan., 34
- restraint in Alzheimer's disease, Jan., 39
- stress thallium imaging, June, 462-463
- Pharmacology
of didanosine, Oct., 711-712
of dideoxycytidine, Oct., 714
of zidovudine, Oct., 706-707
- Pheochromocytoma: and polycythemia, Mar., 186
- Phlebotomy: in polycythemia vera, Mar., 192-193
- Phosphorus: radioactive, in polycythemia vera, Mar., 195
- Physical activity
(*See also* Exercise)
hypertension and, Nov., 804-805
- examination
in cardiac evaluation, June, 362-380
- in incontinence, geriatric urinary, Feb., 103, 106
- in polycythemia vera, Mar., 173
- findings, abnormal, during exercise testing, June, 415
- Physicians: and Alzheimer's disease, Jan., 16
- Physiologic response: postresuscitative, Dec., 861-865
- Pick's disease, Jan., 33
- Pindolol: in Alzheimer's disease, Jan., 39
- Pipobroman: in polycythemia vera, Mar., 195
- Piracetam: in Alzheimer's disease, Jan., 49
- Plaques: neuritic, in Alzheimer's disease, Jan., 41-43
- Platelet
abnormalities in polycythemia vera, Mar., 172-173, 178-179
activating factor, Aug., 594
adhesions
disorders, Aug., 600-603
normal, Aug., 589-592
- aggregation
disorders, Aug., 603-605
fibrinogen and, Aug., 596-597
glycoprotein IIb/IIIa complex and, Aug., 596-597
normal, Aug., 592-597
platelet agonists and, Aug., 592-594
- signal transduction in, Aug., 594-596
- tracings, Aug., 593
- agonists and platelet aggregation, Aug., 592-594
- alpha granules, Aug., 597-598
- deficiency, Aug., 602, 606-607
- dense granules, Aug., 598
- deficiency, Aug., 607-608

- Platelet (cont.)**
- derived growth factor, Aug., 597
 - factor 4, Aug., 597
 - function
 - disorders (*see below*)
 - normal, Aug., 589-599
 - schematic illustrations, Aug., 590
 - function disorders, Aug., 589-631
 - acquired (*see below*)
 - antifibrinolytic agents in, Aug., 622
 - congenital, Aug., 599-609
 - corticosteroids in, Aug., 621
 - DDAVP in, Aug., 620-621
 - estrogens in, conjugated, Aug., 621
 - management, Aug., 619-622
 - nontransfusion therapy for, Aug., 620-622
 - supportive care for, Aug., 619
 - transfusion for, Aug., 619-620
 - function disorders, acquired, Aug., 609-619
 - antibiotics causing, beta lactam, Aug., 612
 - anticoagulants causing, Aug., 612-613
 - antiplatelet antibodies and, Aug., 616-617
 - antithrombotics causing, Aug., 612-613
 - aspirin causing, Aug., 609-611
 - cardiac bypass causing, Aug., 615-616
 - drugs causing, Aug., 609-614
 - drugs causing, nonsteroidal antiinflammatory, Aug., 611
 - dysproteinemias causing, Aug., 617
 - liver disease causing, Aug., 616
 - medical conditions causing, Aug., 614-619
 - myeloproliferative disorders causing, Aug., 617-618
 - thrombolytics causing, Aug., 612-613
 - uremia causing, Aug., 614-615
 - gray platelet syndrome, Aug., 602, 606-607
- lysosomes, Aug., 598
 - membrane protein deficiencies, Aug., 602-603
 - Montreal platelet syndrome, Aug., 602
 - procoagulant activity, Aug., 599
 - disorders, Aug., 608-609
 - secretion
 - disorders, Aug., 605-608
 - disorders due to abnormal secretory mechanism, Aug., 605-606
 - disorders due to platelet granule deficiency, alpha, Aug., 606-607
 - disorders due to platelet granule deficiency, dense, Aug., 607-608
 - normal, Aug., 597-598
- signal transduction pathway in, Aug., 595
- transfusion (*see Transfusion, platelet*)
- Plateletpheresis: in polycythemia vera, Mar., 190
- Platypnea: in cardiac evaluation, June, 358
- Plethora: in polycythemia vera, Mar., 173
- Plethysmograph: body, measurement of airway resistance in, July, 535
- Pleural
- biopsy (*see Biopsy, pleural*)
 - diseases, May, 273-331
 - Churg-Strauss syndrome causing, May, 318
 - collagen vascular diseases causing, May, 317-319
 - immunoblastic lymphadenopathy causing, May, 319
 - Mediterranean fever causing, familial, May, 318-319
 - effusion (*see below*)
 - fluid
 - amylase in exudative pleural effusions, May, 282-283
 - antinuclear antibody measurement in lupus pleuritis, May, 318

- appearance in exudative pleural effusions, May, 281
- cytology (see Cytology, pleural fluid)
- diagnostic tests in exudative pleural effusions, May, 280–284
- formation, experimental studies, May, 276–277
- formation, physiology, May, 273–277
- glucose (see Glucose, pleural fluid)
- lactic dehydrogenase in exudative pleural effusions, May, 283
- lymphatic clearance, May, 275
- movement, pressures influencing, May, 274
- PCO₂ in exudative pleural effusions, May, 284
- pH (see pH, pleural fluid)
- white blood cell count and differential in exudative pleural effusions, May, 281–282
- mesothelioma (see Mesothelioma, pleural)
- space
- amebiasis, May, 309
 - aspergillosis in, May, 307
 - bacterial infections (see Parapneumonic effusions and bacterial infections of pleural space)
 - blastomycosis in, May, 307
 - coccidioidomycosis in, May, 307–308
 - cryptococcosis in, May, 308
 - echinococcosis, May, 310
 - fungal infections, May, 307–309
 - histoplasmosis in, May, 308–309
 - paragonimiasis, May, 310
 - parasitic infections, May, 309–310
- Pleural effusion
- after abdominal surgery, May, 316
 - after abscess, intra-abdominal, May, 315–316
 - in AIDS, May, 311
- approach to patients with, May, 278–280
- asbestos, May, 320
- after bypass surgery, coronary artery, May, 321
- diagnosis, differential, May, 278–279
- dialysis and, peritoneal, May, 290
- diaphragmatic hernia and, May, 316
- drug reactions causing, May, 319
- after esophageal perforation, May, 314–315
- exudative, May, 292–298
- bacteriologic stains in, May, 283
 - biopsy in, needle, May, 285–286
 - open, May, 287
 - bronchoscopy in, May, 286
 - criteria, May, 279
 - culture in, May, 283
 - diagnosis, differential, May, 280–285
 - immunologic studies in, May, 284
 - pleural fluid amylase in, May, 282–283
 - pleural fluid appearance in, May, 281
 - pleural fluid cytology in, May, 282
 - pleural fluid glucose in, May, 282
 - pleural fluid lactic dehydrogenase in, May, 283
 - pleural fluid pH and PCO₂ in, May, 284
 - pleural fluid white cell count and differential in, May, 281–282
 - pleuroscopy in, May, 286
 - undiagnosed, invasive tests for, May, 285–287
- after Fontan procedure, May, 291
- gastrointestinal tract diseases causing, May, 313–316
- heart failure causing, congestive, May, 287–288
- clinical manifestations, May, 287–288

- Pleural effusion (cont.)**
- diagnosis, May, 288
 - pathophysiology, May, 287
 - treatment, May, 288
 - in hepatic hydrothorax (see *Hepatic hydrothorax, hepatic*)
 - incidence, annual, May, 280
 - malignant, May, 292–296
 - clinical manifestations, May, 292–293
 - diagnosis, May, 293–294
 - pathogenesis, May, 292
 - treatment, May, 294–296
 - in Meige syndrome, May, 323–324
 - miscellaneous causes, May, 320–324
 - myxedema and, May, 291
 - in nephrotic syndrome, May, 290
 - pancreatic, chronic, May, 314
 - in pancreatitis, acute, May, 313
 - pericardial disease causing, May, 321
 - in pneumonia, primary atypical, May, 311
 - postcardiac injury syndrome causing, May, 320–321
 - in pulmonary embolism, May, 312–313
 - clinical manifestations, May, 312–313
 - diagnosis, May, 313
 - treatment, May, 313
 - Q fever causing, May, 312
 - in rickettsial infections, May, 311–312
 - sarcoid, May, 322–323
 - after sclerotherapy, endoscopic variceal, May, 316
 - transudative, May, 287–291
 - trapped lung causing, May, 323
 - tuberculous, May, 304–306
 - clinical manifestations, May, 305
 - diagnosis, May, 306
 - pathogenesis, May, 305
 - treatment, May, 306
 - uremic, May, 321–322
 - in urinothorax, May, 291
 - vena caval syndrome and, superior, May, 290–291
 - in viral infections, May, 311–312
 - in yellow nail syndrome, May, 322
- Pleurectomy: parietal, in yellow nail syndrome, May, 322**
- Pleuritis**
- lupus, May, 317–318
 - rheumatoid, May, 317
- Pleurodesis in pleural effusion**
- after Fontan procedure, May, 291
 - malignant, May, 294, 295, 296
 - in yellow nail syndrome, May, 322
- Pleuroperitoneal shunt (see Shunt, pleuroperitoneal)**
- Pleuroscopy: in exudative pleural effusions, May, 286**
- Pneumocystis carinii* disease: in AIDS, Oct., 721–726**
- Pneumonia**
- Pneumocystis carinii*, in AIDS, Oct., 721–726
 - primary atypical, pleural effusions in, May, 311
- Polycystic renal disease: and polycythemia, Mar., 186**
- Polycythemia**
- classification, Mar., 184
 - relative, Mar., 183
 - secondary, Mar., 184–185
 - erythropoietin production increase causing, appropriate, Mar., 185–186
 - erythropoietin production increase causing, inappropriate, Mar., 186
 - hypoxemia causing, arterial, Mar., 185
 - laboratory findings compared to findings in polycythemia vera, Mar., 188
 - oxygen delivery defects causing, Mar., 185–186
 - spurious, Mar., 183
 - stress, Mar., 183
 - vera, Mar., 165–212
 - age and, Mar., 170
 - alkylating agents in, Mar., 195
 - bone marrow in, cytogenetics of, Mar., 182

- bone marrow in, location of, Mar., 179-181
bone marrow in, morphology of, Mar., 181
bone marrow in, MRI of, Mar., 181
busulfan in, Mar., 196
clinical course, Mar., 197-199
clinical features, Mar., 170-173
coagulation in, Mar., 178-179
diagnosis, differential, Mar., 183-189
diagnosis, Polycythemia Vera Study Group Criteria, Mar., 186-188
erythroid colonies in, Mar., 168
etiology, Mar., 165-170
granulocytes in, Mar., 177-178
hydroxyurea in, Mar., 193-195
hydroxyurea in, red cell volume increase after, Mar., 176
interferon in, Mar., 196
laboratory findings in, Mar., 173-183
laboratory findings in, comparison to findings in secondary polycythemia, Mar., 188
laboratory findings in, miscellaneous, Mar., 182-183
laboratory findings in, spurious, Mar., 183
leukemia in, acute and chronic myeloid, Mar., 198
leukocyte alkaline phosphatase in, Mar., 178
management, acute, Mar., 189-191
management, chronic, Mar., 191-197
myeloid metaplasia after (see Myeloid metaplasia, post-polycythemic)
myelosuppressive therapy in, Mar., 193-196
occult, and thrombocytosis, Mar., 175
pathogenesis, Mar., 165-170
phlebotomy in, Mar., 192-193
phosphorus in, radioactive, Mar., 195
physical examination in, Mar., 173
platelet abnormalities in, Mar., 178-179
platelet dysfunction in, Aug., 618
progression from essential thrombocythemia, Mar., 190
proliferative phase, Mar., 166-169
spent phase, Mar., 169-170
spent phase, clinical course, Mar., 198-199
therapy, Mar., 189-197
variant presentations, Mar., 189
vitamin B₁₂ in, serum, Mar., 178
Polymerase chain reaction: for HIV infection, Sept., 678-679
Polyneuropathy: peripheral, in multiple organ failure syndrome, Dec., 886-887
Positron emission tomography (see Tomography, positron emission)
Postcardiac injury syndrome: pleural effusions in, May, 320-321
Postresuscitative metabolism, Dec., 865-872
Postresuscitative physiologic response, Dec., 861-865
Potassium intake increase in hypertension, Nov., 805-806
serum, in polycythemia vera, Mar., 183
Power of attorney: and Alzheimer's disease, Jan., 37
Pox virus infection: in AIDS, Oct., 736
Praziquantel: in pleural paragonimiasis, May, 310
Prednisolone: in tuberculous pleural effusions, May, 306
Prednisone: in *Pneumocystis carinii* disease in AIDS, Oct., 722
Pregnancy aspirin and platelet dysfunction, Aug., 611

- Pregnancy (cont.)
- induced hypertension and calcium supplements, Nov., 806
 - polycythemia vera and, Mar., 197
- Prerenal azotemia: after resuscitation, Dec., 872
- Primaquine-clindamycin: in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
- Procarbazine: causing pleural effusion, May, 319
- Propranolol
- in Alzheimer's disease, Jan., 39
 - platelet dysfunction due to, Aug., 613
- Prostacyclin, Aug., 595–596
- analogues in cardiac bypass surgery, Aug., 616
- Prostaglandin endoperoxide-induced platelet aggregation, Aug., 594
- Prostate
- cancer (see Cancer, prostate)
 - enlargement and urinary flow rates, in elderly, Feb., 87
 - specific antigen (see Antigen, prostate-specific)
- Prostatitis: chronic, after chronic indwelling catheter, in elderly, Feb., 136
- Prostitutes: and HIV, Sept., 660
- Protein
- amyloid precursor, in Alzheimer's disease, Jan., 43
 - catabolism, total body, after resuscitation, Dec., 871–872
 - induced storage pool deficiency, eosinophil, Aug., 619
 - platelet membrane, deficiencies, Aug., 602–603
- Prothrombin time: in polycythemia vera, Mar., 179
- Protozoan infections: in AIDS, Oct., 721–730
- Pruritus: in polycythemia vera, Mar., 171
- Pseudohypoparathyroidism: and dementia, Jan., 31
- Psychological health: effect of geriatric urinary incontinence on, Feb., 82–83
- Public health impact: of Alzheimer's disease, Jan., 13–16
- Pulmonary
- (See also Lung)
 - apoplexy, June, 361
 - embolism
 - acute, ECG in, June, 391
 - pleural effusion in (see Pleural effusion, in pulmonary embolism)
 - fibrosis, compliance in, July, 523
 - hypertension, chest pain in, June, 359
 - infarction causing hemoptysis in mitral stenosis, June, 361–362
 - involvement in multiple organ failure syndrome, Dec., 862–863
 - vascular disease and exercise, July, 570–571
 - gas exchange and, abnormal, July, 569
- Pulmonic stenosis: on chest radiography, June, 406–407
- Pulse
- arterial
 - in cardiac evaluation, June, 366–368
 - wave configuration in cardiac evaluation, abnormal, June, 367–368
 - wave configuration in cardiac evaluation, normal, June, 366–367
 - bisferiens, June, 367
 - Corrigan's, June, 367
- Pulsus
- alternans, June, 367
 - paradoxus, June, 367–368
 - tardus, June, 367
- Purpura, idiopathic thrombocytopenic
- antiplatelet antibodies and, Aug., 617
 - Bernard-Soulier-like syndrome and, Aug., 602

- P wave, June, 386
 Pyelogram, IV
 in hypertension, renovascular, Nov., 821
 in unknown primary malignancy, Apr., 229
 Pyelonephritis: after chronic indwelling catheters, in elderly, Feb., 136
 Pyrimethamine
 in isosporiasis in AIDS, Oct., 730
 in toxoplasmosis in AIDS, Oct., 727-728
 Pyruvate production: after resuscitation, Dec., 867-869
 Pyuria: in elderly men, Feb., 106

Q

- Q fever: causing pleural effusions, May, 312
 QRS complex, June, 386-387

R

- Radiation (see Irradiation)
 Radioactive phosphorus: in polycythemia vera, Mar., 195
 Radiography
 chest
 atrial enlargement on, June, 401-402, 403
 cardiac appearance on, normal, June, 398-399
 cardiac appearance on, normal, on frontal projection, June, 398-399
 cardiac appearance on, normal, on lateral projection, June, 399, 400
 cardiac chamber enlargement on, June, 399-402
 in cardiac evaluation, June, 397-410
 coarctation of aorta on, June, 407-409
 in heart disease, congenital, June, 405-409
 in heart failure, congestive, June, 402-405
 in heart failure, congestive, early, June, 403-404
 pericardial disease on, June, 409-410
 pericardial effusion on, June, 409-410
 pericarditis on, constrictive, June, 410, 411
 in *Pneumocystis carinii* pneumonia in AIDS, Oct., 721-722
 pulmonic stenosis on, June, 406-407
 pulmonary edema on, June, 404-405
 septal defect on, atrial, June, 406, 407
 septal defect on, ventricular, June, 406
 ventricular enlargement on, left, June, 401, 402
 ventricular enlargement on, right, June, 401
 contrast agents causing platelet dysfunction, Aug., 613
 gastrointestinal, in unknown primary malignancy, Apr., 229
 in incontinence, geriatric urinary, Feb., 113
 Radioimmunoprecipitation assays: in HIV diagnosis, Sept., 675
 Radiology
 in Alzheimer's disease, Jan., 23-26
 functional imaging, Jan., 25-26
 morphologic imaging, Jan., 23-25
 in malignancy of unknown origin, Apr., 229
 Radionuclide
 angiogram, equilibrium, June, 456-457
 scans in unknown primary malignancy, Apr., 229-230
 Rectal electrical stimulator: in geriatric urinary incontinence, Feb., 134
 Red cell
 mass
 correlation between hematocrit and, Mar., 174

- Red cell (cont.)**
- increased, and increased hematocrit, in differential diagnosis of polycythemia vera, Mar., 184-188
 - normal, and increased hematocrit, in differential diagnosis of polycythemia vera, Mar., 183-184
 - transfusion for anemia in post-polycythemic myeloid metaplasia, Mar., 201-202
 - volume increase after hydroxyurea in polycythemia vera, Mar., 176
- Reflexes:** primitive, in Alzheimer's disease, Jan., 23
- Regurgitant valvular lesions:** echocardiography in, June, 434-440
- Regurgitation**
- aortic (see Aortic, regurgitation)
 - mitral (see Mitral, regurgitation)
 - tricuspid (see Tricuspid, regurgitation)
- Rehabilitation:** after multiple organ failure syndrome, Dec., 886-887
- Relaxants:** bladder, in geriatric urinary incontinence, Feb., 130
- Renal (see Kidney)**
- Renin activity:** plasma, and hypertension, Nov., 793-794
- Renovascular hypertension (see Hypertension, renovascular)**
- Reperfusion injury:** mediators of, Dec., 874
- Residual volume, July, 527**
- Respiratory**
- acid-base disturbances, July, 562-563
 - acidemia, July, 562
 - acidosis, July, 562
 - alkalemia, July, 563
 - alkalosis, July, 563
 - cardiorespiratory adaptation to exercise, July, 566-571
 - poor cooperation and, July, 571
 - distress syndrome, adult, platelet dysfunction in, Aug., 618-619
- frequency increase, effect on dynamic lung compliance, July, 548**
- function evaluation in health and disease, July, 519-576**
- appendix, July, 573-576
- muscle**
- endurance assessment, July, 552
 - fatigue, July, 553
 - function tests, July, 552
 - strength assessment, July, 552
- quotient during exercise, July, 570**
- rate**
- effect on alveolar ventilation, July, 554
 - during exercise, relation to tidal volume, July, 568
- response**
- to carbon dioxide, July, 564-565
 - to hypoxemia, July, 565
- Respite care:** in Alzheimer's disease, Jan., 35-36
- Restraint:** pharmacologic, in Alzheimer's disease, Jan., 39
- Resuscitation**
- metabolism after, Dec., 865-872
 - physiologic response after, Dec., 861-865
- Reticulin:** in polycythemia vera, Mar., 181
- Reverse transcriptase inhibitors:** in AIDS, Oct., 715-716
- Rheumatoid pleuritis, May, 317**
- Rib notching:** on chest radiograph in coarctation of aorta, June, 408-409
- Ribonucleic acid:** in multiple organ failure syndrome therapy, Dec., 885
- Rickettsial infections:** causing pleural effusions, May, 311-312
- Rifampin:** in tuberculous pleural effusions, May, 306
- Ristocetin:** and platelet adhesion, Aug., 591-592
- Rod:** Harrington, for spinal fusion, and DDAVP, Aug., 621

Romhilt-Estes ECG point system:
for left ventricular hypertrophy, June, 389

Rub: pericardial friction, June, 374,
377

Ruddy cyanosis: in polycythemia
vera, Mar., 173

S

Salmonella infections: in AIDS, Oct.,
744

Sarcoidosis
biopsy in, endomyocardial, June,
488

pleural effusion due to, May,
322-323

Sarcoma
Kaposi's, in AIDS, Oct., 746-748
pleural effusions and, May,
311

soft-tissue, cytogenetic analysis,
Apr., 241

Scan (see Imaging)

Sclerosing cholangitis: with papillary
stasis due to cytomegalovirus in AIDS, Oct., 731

Sclerotherapy: endoscopic variceal,
pleural effusions after, May,
316

Sedating neuroleptics: for sleep/
wake disturbances in Alzheimer's disease, Jan., 38

Seizures
didanosine-induced, Oct., 713
zidovudine overdosage causing,
Oct., 710

Septal defect

atrial
echocardiography in, June,
453-454

echocardiography in, transesophageal, June, 428
on radiography, chest, June,
406, 407

ventricular
echocardiography in, June,
453-454
on radiography, chest, June,
406

Serotonin-induced platelet aggregation, Aug., 594

Sexual transmission: of HIV, Sept.,
659-661

Sexually transmitted diseases: and
HIV transmission, Sept., 661
Shigella infections: in AIDS, Oct.,
745

Shingles: and HIV infection, Sept.,
671

Shock

heat shock genes in multiple organ
failure syndrome, Dec., 878

warm, June, 380

Shunt

pleuroperitoneal, for pleural effusions
after Fontan procedure, May,
291

in heart failure, congestive,
May, 288

malignant, May, 295-296

in yellow nail syndrome, May,
322

right-to-left, and polycythemia,
Mar., 185

true, July, 558-559

Single photon emission tomography
(see Tomography, single photon emission)

SIRS (see Systemic inflammatory
response syndrome)

Skin

problems due to geriatric urinary
incontinence, Feb., 82

testing, tuberculin, in AIDS, Oct.,

739

Sleep

apnea and drug therapy in hypertension, Nov., 824-825
disturbances in Alzheimer's disease, management, Jan., 38

Sling procedure: for stress urinary
incontinence, in elderly, Feb.,
131

Smoking

Alzheimer's disease and, Jan., 15
cessation and hypertension, Nov.,
795, 798-799

- Smoking (cont.)**
- hypercholesterolemia and, Nov., 789
 - neuroendocrine carcinoma and, poorly differentiated, in men, Apr., 252
 - polycythemia due to, Mar., 186
 - Social well-being: effect of geriatric urinary incontinence on, Feb., 82-83
 - Sodium restriction: in hypertension, Nov., 800-803
 - Soft-tissue sarcoma: cytogenetic analysis, Apr., 241
 - Sokolow-Lyons ECG criteria: for left ventricular hypertrophy, June, 389
 - Solid tumors: chromosomal abnormalities in, Apr., 242
 - Somatostatin
 - in Alzheimer's disease, Jan., 46-47
 - analogues in cryptosporidiosis in AIDS, Oct., 729
 - Sound(s)
 - breath, June, 378-379
 - heart
 - first, June, 369-372
 - fourth, June, 372
 - second, June, 369-372
 - second, causes of exaggerated or reversed splitting of, June, 371
 - third, June, 372
 - wave imaging, principles, June, 417-419
 - SPECT (see Tomography, single photon emission)
 - Speech disturbances: in parkinsonian dementia, Jan., 33
 - Sphincters: artificial, in geriatric urinary incontinence, Feb., 133
 - Spinal fusion: Harrington rod, DDAVP in, Aug., 621
 - Spiramycin in AIDS
 - for cryptosporidiosis, Oct., 729
 - for toxoplasmosis, Oct., 728
 - Spirometry: prediction equations for, July, 574
 - Spleen
 - enlargement
 - in myeloid metaplasia, post-polycythemic, therapy, Mar., 203-204
 - in polycythemia vera, Mar., 173
 - irradiation in postpolycythemic myeloid metaplasia, Mar., 204
 - Splenectomy in postpolycythemic myeloid metaplasia, Mar., 203
 - leukemia after, acute, Mar., 201
 - Spongiform encephalopathy, Jan., 34
 - Squamous cell carcinoma: of unknown primary origin, Apr., 249
 - Squatting: cardiac auscultation during, June, 377
 - Stains
 - bacteriologic, in exudative pleural effusions, May, 283
 - immunocytochemical (see Immunocytochemistry)
 - Stanford bioptome: in endomyocardial biopsy, June, 488-489
 - Staphylococcus aureus* infections: in AIDS, Oct., 744
 - Stenosis
 - aortic
 - cardiac catheterization in, June, 473-476
 - echocardiography in, June, 433-434
 - mitral
 - cardiac catheterization in, June, 470-473
 - echocardiography in, June, 431-433
 - hemoptysis due to, June, 361-362
 - papillary, with sclerosing cholangitis due to cytomegalovirus in AIDS, Oct., 731
 - pulmonic: on chest radiography, June, 406-407
 - tricuspid, cardiac catheterization in, June, 473
 - Stenotic lesions: echocardiography in, June, 431-434

- Steroids**
(See also Corticosteroids)
 anabolic, for anemia in postpolycythemic myeloid metaplasia, Mar., 202
- Stones:** urinary, after chronic indwelling catheter, in elderly, Feb., 136
- Streptococcus pneumoniae infections:** in AIDS, Oct., 744
- Streptokinase:** in parapneumonic effusions, May, 303
- Stress**
 echocardiography, June, 450–451
 incontinence (*see* Incontinence, urinary, geriatric, stress)
 management in hypertension, Nov., 806–808
 pharmacologic, for thallium imaging, June, 462–463
 polycythemia, Mar., 183
- Stroke**
 bilateral, and dementia, Jan., 29
 effect of drug therapy in hypertension on, Nov., 811
 potassium intake and, Nov., 805
- Strongyloidiasis:** disseminated, in AIDS, Oct., 730
- ST segment** (*see* Electrocardiography, exercise, ST segment on)
- Subdiaphragmatic unknown primary malignancy:** pathologic evaluation, Apr., 244
- Sulfa:** triple, in toxoplasmosis in AIDS, Oct., 727–728
- Sulfadiazine:** in toxoplasmosis in AIDS, Oct., 727–728
- Supportive care:** for platelet function disorders, Aug., 619
- Supradiaphragmatic unknown primary malignancy:** pathologic evaluation, Apr., 243–244
- Surface markers:** in unknown primary malignancy, Apr., 243
- Surgery:** abdominal, pleural effusion after, May, 316
- Sweating:** in polycythemia vera, Mar., 171
- Syncope:** in cardiac evaluation, June, 359–360
- Syphilis:** and AIDS, Oct., 745
- Systemic inflammatory response syndrome**
(See also Multiple organ failure syndrome)
 discussion of term, Dec., 857
- Systolic function, echocardiography of** (*see* Echocardiography, of systolic function)

T

- Tachycardia:** multifocal atrial, in cor pulmonale, June, 392
- Talc:** in malignant pleural effusions, May, 295
- Tamponade, cardiac**
 cardiac catheterization in, June, 486–487, 488, 489
 echocardiography in, June, 454
- T cell(s)**
 in AIDS, Sept., 652–654
 lymphotrophic virus-I/II infection, human, in AIDS, Oct., 736
- Technetium-99m MIBI myocardial perfusion imaging,** June, 463
- Teflon injections:** periurethral, in geriatric urinary incontinence, Feb., 132
- Terodiline:** in geriatric urinary incontinence, Feb., 127–130
- Tetracycline:** in malignant pleural effusions, May, 294–295
- Tetrahydroaminoacridine:** in Alzheimer's disease, Jan., 48
- Tetrahydroimidazobenzodiazepine compounds:** in AIDS, Oct., 715–716
- Thalamic involvement:** in dementia, Jan., 29
- Thallium imaging,** June, 460–463
 exercise, June, 461–462
 pharmacological stress, June, 462–463
- Theophylline toxicity:** causing multifocal atrial tachycardia, June, 392

- Thioridazine:** in Alzheimer's disease, Jan., 38
Thoracoscopy: in malignant mesothelioma diagnosis, May, 297
Thrills: June, 369
Thrombasthenia: Glanzmann, Aug., 603-605
Thrombi
 atrial, echocardiography in, June, 452-453
 transesophageal, June, 427-428
 ventricular, echocardiography in, June, 452-453
Thrombin: platelet receptor for, Aug., 592
Thrombocythemia, essential
 age and, Mar., 170
 progression to polycythemia vera, Mar., 190
Thrombocytopenia
 HIV-associated, zidovudine in, Oct., 709
 in postpolycythemia myeloid metaplasia, therapy, Mar., 203
Thrombocytopenic purpura (see
 Purpura, idiopathic thrombocytopenic)
Thrombocytosis: and occult polycythemia vera, Mar., 175
 β -Thromboglobulin, Aug., 597
Thrombolytics
 in parapneumonic effusions, May, 303
 platelet dysfunction due to, Aug., 612-613
Thrombosis: hepatic vein, and polycythemia vera, Mar., 171
Thrombospondin: Aug., 597-598
Thrombotic complications: in polycythemia vera, Mar., 171-172
Thrush: oral, in AIDS, Oct., 740
Thyroid scans: in unknown primary malignancy, Apr., 229-230
TIBO compounds: in AIDS, Oct., 715-716
Ticlopidine: effect on platelet function, Aug., 613
Tidal volume
 effect on alveolar ventilation, July, 554
 related to respiratory rate during exercise, July, 568
Tissue perfusion: in cardiac evaluation, June, 380
Toilet substitutes: in geriatric urinary incontinence, Feb., 119
Toileting: scheduled, for geriatric urinary incontinence, Feb., 124
Tomography
 computed
 in Alzheimer's disease, Jan., 25
 differentiating lung abscess from empyema, May, 301
 in malignancy of unknown primary origin, Apr., 228-229
 in mesothelioma, malignant, May, 296
 in Pick's disease, Jan., 33
 positron emission
 in Alzheimer's disease, Jan., 25
 in dementia, hydrocephalic, symptomatic, Jan., 30
 in dementia, vascular, Jan., 30
 in Huntington's disease, Jan., 34
 in Pick's disease, Jan., 33
 single photon emission
 in Alzheimer's disease, Jan., 25-26
 in dementia, vascular, Jan., 30
 in Pick's disease, Jan., 33
Total lung capacity: subdivisions of lung volume as proportion of, July, 526
Toxicity
 cardiotoxicity, doxorubicin, endomyocardial biopsy in, June, 488
 didanosine, Oct., 713
 dideoxycytidine, Oct., 715
 drug, causing dementia, Jan., 27-28
 foscarnet, Oct., 732-733
 theophylline, causing multifocal atrial tachycardia, June, 392
 zidovudine, Oct., 709-710

- Toxoplasmosis: in AIDS, Oct., 726–728
- Tranexamic acid: for platelet function disorders, Aug., 622
- Transcobalamins: in polycythemia vera, Mar., 177–178
- Transcriptase inhibitors: reverse, in AIDS, Oct., 715–716
- Transesophageal echocardiography, June, 425–428
- Transfusion
- associated HIV, Sept., 663–664
 - platelet
 - in cardiac bypass surgery, Aug., 616
 - in platelet function disorders, Aug., 619–620
 - red cell, for anemia in postpolycythemic myeloid metaplasia, Mar., 201–202
- Transplacental transmission: of HIV, Sept., 663
- Transplantation
- bone marrow, in Glanzmann's thrombasthenia, in children, Aug., 605
 - HIV transmission by, Sept., 664
- Trapped lung: causing pleural effusion, May, 323
- Trauma: head, as risk factor in Alzheimer's disease, Jan., 15
- Trazodone: in Alzheimer's disease, Jan., 39
- Treadmill testing: post myocardial infarction, June, 416
- Tricuspid regurgitation
- cardiac catheterization in, June, 481
 - echocardiography in, June, 437–440
 - stenosis, cardiac catheterization in, June, 473
- Trifluridine: topical, in herpes simplex virus infection in AIDS, Oct., 734
- Triglycerides: pleural fluid, in exudative pleural effusions, May, 284
- Trimethoprim
- dapsone in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
 - sulfamethoxazole
 - in isosporiasis in AIDS, Oct., 730
 - in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
 - prophylactic, in *Pneumocystic carinii* disease in AIDS, Oct., 726
- Trimetrexate: in *Pneumocystis carinii* disease in AIDS, Oct., 723
- Tube(s) (see Chest, tubes)
- Tuberculin skin testing: in AIDS, Oct., 739
- Tuberculous pleural effusion (see Pleural effusion, tuberculous)
- Tumor
- germ cell (see Germ cell tumor)
 - heart (see Heart, tumors)
 - host interactions during metastatic cascade, Apr., 224
 - kidney, and polycythemia, Mar., 186
 - markers in unknown primary malignancy, Apr., 230–234
 - solid, chromosomal abnormalities in, Apr., 242
- T wave, June, 387
- Twin studies: in Alzheimer's disease, Jan., 26

U

- Ubiquitin: in neurofibrillary tangles in Alzheimer's disease, Jan., 44
- Ulcer
- esophageal, zidovudine-induced, Oct., 710
 - peptic, and polycythemia vera, Mar., 171
- Ultrasound: for residual urine measurement in geriatric incontinence, Feb., 110
- Unknown primary malignancy, Apr., 221–260
- biologic principles, Apr., 245–246

- Unknown primary malignancy (*cont.*)
- CT in, Apr., 228-229
 - cytogenetic analysis, Apr., 241-242
 - detection, Apr., 222-223
 - diagnosis, Apr., 227-244
 - flow schema for, Apr., 247
 - summary, Apr., 246
 - diagnostic studies, Apr., 228-230
 - molecular, Apr., 243
 - DNA probes in, Apr., 243
 - evaluation, Apr., 227-244
 - hormonal receptors in, Apr., 241
 - imaging in, Apr., 229
 - immunocytochemistry in, Apr., 235-240
 - screening panel of, Apr., 238-239
 - incidence, Apr., 222-223
 - individual syndromes, Apr., 249-254
 - metastatic involvement in, Apr., 223
 - microscopy in
 - electron, Apr., 240-241
 - light, Apr., 235
 - MRI, in, Apr., 230
 - pathologic evaluation, Apr., 234-244
 - based on anatomic distribution, Apr., 243-244
 - radiology in, Apr., 229
 - radionuclide scans in, Apr., 229-230
 - subdiaphragmatic, pathologic evaluation, Apr., 244
 - summary, Apr., 254-255
 - supradiaphragmatic, pathologic evaluation, Apr., 243-244
 - surface markers in, Apr., 243
 - survival after, Apr., 227
 - treatment, Apr., 246-249
 - flow schema for, Apr., 247
 - tumor markers in, Apr., 230-234
- Unknown primary origin
- adenocarcinoma of, Apr., 252, 254
 - chemotherapy, Apr., 248
 - carcinoma of
 - neuroendocrine, poorly differentiated, Apr., 251-252
 - squamous cell, Apr., 249
- germ cell tumors of (see Germ cell tumor)
- lymphoma of, large-cell, Apr., 250-251
- malignancy of (see Unknown primary malignancy above)
- mesothelioma of
 - ovarian, Apr., 253-254
 - peritoneal, Apr., 252-253
- Uracil
- in multiple organ failure syndrome, Dec., 885
 - mustard in polycythemia vera, Mar., 195
- Ureagenesis: after resuscitation, Dec., 872
- Uremia
- platelet dysfunction in, Aug., 614-615
 - pleural effusion due to, May, 321-322
- Urethra
- (*See also Periurethral*)
 - pressure
 - age and, in women, Feb., 87
 - profile in geriatric urinary incontinence, Feb., 116-117
- Uric acid: in polycythemia vera, Mar., 182
- Urinary
- continence (see Continence, urinary)
 - incontinence (see Incontinence, urinary)
 - sphincters, artificial, in geriatric incontinence, Feb., 133
 - stones after chronic indwelling catheter, in elderly, Feb., 136
 - tract
 - infections due to catheters, chronic indwelling, in elderly, Feb., 136
 - infections due to incontinence, in elderly, Feb., 82
 - lower, abnormalities underlying incontinence, Feb., 93
 - lower, innervation of, basic, Feb., 85
 - lower, normal pressure volume relationships in, Feb., 86

- lower, pathology, after chronic indwelling catheter, in elderly, Feb., 136
Urination
 age-related changes in, Feb., 87-92
 normal, Feb., 83-87
 anatomic components, Feb., 84
Urine
 residual, measurement in geriatric incontinence, Feb., 110
 specimen in diagnostic evaluation of geriatric incontinence, Feb., 106
Urinothorax, May, 291
Urodynamic testing in geriatric urinary incontinence complex, Feb., 113, 116-117 simple, Feb., 111
Uroflowmetry in geriatric urinary incontinence, Feb., 116
Urokinase: in parapneumonic effusions, May, 303
Uterine myomas: and polycythemia, Mar., 186
- V**
- Vaccines**: in AIDS, Oct., 720
Vaccinia virus infection: in AIDS, Oct., 736
Vaginitis: *Candida*, in AIDS, Oct., 740, 741
Valsalva: cardiac auscultation during, June, 377
Valve
 aortic (see Aortic)
 mitral (see Mitral)
 tricuspid (see Tricuspid)
Valvular
 heart disease (see Heart, disease, valvular)
 lesions, regurgitant, echocardiography in, June, 434-440
Variceal sclerotherapy: endoscopic, pleural effusions after, May, 316
Varicella-zoster virus infection: in AIDS, Oct., 734-735
- Varices**: bronchial, causing hemoptysis in mitral stenosis, June, 361
Vascular
 cardiovascular (see Cardiovascular)
 cerebrovascular amyloid in Alzheimer's disease, Jan., 43
 dementia, Jan., 29-30
 disease
 collagen, causing pleural disease, May, 317-319
 pulmonary, and exercise, July, 570-571
 pulmonary, and exercise, abnormal gas exchange during, July, 569
 resistance, systemic, in multiple organ failure syndrome, Dec., 864
Vasculitis: and dementia, Jan., 32
Vasopressin-induced platelet aggregation, Aug., 594
Vein
(See also Venous)
 bronchial, varices, causing hemoptysis in mitral stenosis, June, 361
 hepatic, thrombosis, and polycythemia vera, Mar., 171
Vena caval syndrome: superior, and pleural effusions, May, 290-291
Venous
(See also Vein)
 admixture
 -like perfusion, July, 557-558
 true, July, 558-559
 pressure(s)
 in cardiac evaluation, June, 362-365
 wave configuration in cardiac evaluation, abnormalities, June, 364-365
 wave-configuration in cardiac evaluation, normal, June, 362-364
Ventilation
 alveolar, July, 553-555
 dead-space-like, July, 558

- Ventilation (*cont.*)
 distribution, July, 555-556
 in upright lung, July, 556
 maximum voluntary, July, 538
 /perfusion mismatch, July, 557-558
- Ventilatory
 abnormality, patterns of, July,
 538-553
 function
 disturbances in obstructive and
 restrictive disease, July, 538
 tests, July, 521-538
 limitation during exercise, July,
 566-568
 pattern
 obstructive, July, 539, 540-541
 obstructive, post-
 bronchodilator studies, July,
 540, 541, 542
 restrictive, July, 538-539
- Ventricle
 contraction beats, premature,
 auscultation after, June, 378
 left
 dilatation, echocardiography,
 June, 447
 enlargement, on chest radiograph,
 June, 401, 402
 hypertrophy (see Hypertrophy,
 ventricular, left)
 impulse, apical, June, 368
 systolic function, echocardiography
 of (see Echocardiography,
 of systolic function, left
 ventricular)
 right
 dilatation, echocardiography,
 June, 447-448
 enlargement, on chest radiograph,
 June, 401
 function evaluation by first-
 pass radionuclide studies,
 June, 458-459
 hypertrophy (see Hypertrophy,
 ventricular, right)
 impulse, June, 369
 systolic function, echocardiography,
 June, 445-446
 septal defect (see Septal defect,
 ventricular)
- thrombi, echocardiography in,
 June, 452-453
- Ventriculography, left, June,
 467
 interpretation, June, 468-469
- Verapamil: in multifocal atrial
 tachycardia, June, 392
- Vessel (see Vascular)
- Vidarabine: in herpes simplex infection in AIDS, Oct., 734
- Virus
 adenovirus infection in AIDS,
 Oct., 736
 culture in HIV diagnosis, Sept.,
 677-678
 cytomegalovirus infection in
 AIDS, Oct., 730-733
 Epstein-Barr virus infection in
 AIDS, Oct., 735
 herpes (see Herpes)
 immunodeficiency, human (see
 HIV)
 infections
 in AIDS, Oct., 730-736
 pleural effusion due to, May,
 311-312
 lymphotrophic, HTLV-I/II infection in AIDS, Oct., 736
 papillomavirus infection in AIDS,
 Sept., 671; Oct., 735-736
 papovavirus infection in AIDS,
 Oct., 736
 pox virus infection in AIDS, Oct.,
 736
 vaccinia virus infection in AIDS,
 Oct., 736
 varicella-zoster virus infection in
 AIDS, Oct., 734-735
- Visual abnormalities: in polycythemia vera, Mar., 171
- Vital capacity, July, 531
 forced (see Forced vital capacity)
- Vitamin B₁₂: serum, in polycythemia vera, Mar., 177-178
- Voiding
 difficulty, in elderly, Feb., 90
 prompted, for geriatric urinary incontinence, Feb., 125-127
- von Willebrand factor, Aug., 591

W

- Wake disturbances: in Alzheimer's disease, management, Jan., 38
Warm shock, June, 380
Wave
 P, June, 386
 sound wave imaging, principles, June, 417-419
 T, June, 387
Weakness: in polycythemia vera, Mar., 171
Weight
 loss in polycythemia vera, Mar., 171
 reduction in hypertension, Nov., 799-800
Well-being: social, effect of geriatric urinary incontinence on, Feb., 82-83
Western blot: in HIV diagnosis, Sept., 673-675
White blood cell (see Leukocyte)
Winter bronchitis: causing hemoptysis in mitral stenosis, June, 362

Workers: health care, HIV transmission to, Sept., 665-667

Y

- Yellow nail syndrome: causing pleural effusion, May, 322

Z

- Zidovudine in AIDS, Oct., 706-711
 acyclovir combined with, Oct., 716
 clinical use, Oct., 707-709
 interferon alpha combined with, Oct., 716
 leukoplakia regression after, oral hairy, Oct., 735
 mechanism of action, Oct., 706
 pharmacology, Oct., 706-707
 resistance, Oct., 710-711
 toxicity, Oct., 709-710
Zoster virus infection: in AIDS, Sept., 671; Oct., 734-735